<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">J Endocr Soc</journal-id>
<journal-id journal-id-type="iso-abbrev">J Endocr Soc</journal-id>
<journal-id journal-id-type="publisher-id">jes</journal-id>
<journal-title-group>
<journal-title>Journal of the Endocrine Society</journal-title>
</journal-title-group>
<issn pub-type="epub">2472-1972</issn>
<publisher>
<publisher-name>Oxford University Press</publisher-name>
<publisher-loc>US</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">32099951</article-id>
<article-id pub-id-type="pmc">7033038</article-id>
<article-id pub-id-type="doi">10.1210/jendso/bvz039</article-id>
<article-id pub-id-type="publisher-id">bvz039</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Invited Mini-Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Intestinal Barrier Dysfunction, LPS Translocation, and Disease Development</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Ghosh</surname>
<given-names>Siddhartha S</given-names>
</name>
<xref ref-type="aff" rid="AF0001">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Jing</given-names>
</name>
<xref ref-type="aff" rid="AF0001">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yannie</surname>
<given-names>Paul J</given-names>
</name>
<xref ref-type="aff" rid="AF0002">2</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">http://orcid.org/0000-0001-9470-6933</contrib-id>
<name>
<surname>Ghosh</surname>
<given-names>Shobha</given-names>
</name>
<xref ref-type="aff" rid="AF0001">1</xref>
<xref ref-type="aff" rid="AF0002">2</xref>
<xref ref-type="corresp" rid="c1"></xref>
<email>shobha@vcu.edu</email>
</contrib>
</contrib-group>
<aff id="AF0001"><label>1</label>
<institution>Department of Internal Medicine, VCU Medical Center</institution>, Richmond, Virginia</aff>
<aff id="AF0002"><label>2</label>
<institution>Hunter Homes McGuire VA Medical Center</institution>, Richmond, Virginia</aff>
<author-notes>
<corresp id="c1"><bold><italic>Correspondence:</italic></bold> Shobha Ghosh, PhD, FAHA, Professor of Medicine and Physiology, Department of Internal Medicine, VCU Medical Center, Richmond, Virginia 23298-0050. E-mail: <email>shobha@vcu.edu</email>.</corresp>
</author-notes>
<pub-date pub-type="collection">
<day>01</day>
<month>2</month>
<year>2020</year>
</pub-date>
<pub-date iso-8601-date="2020-02-20" pub-type="epub">
<day>20</day>
<month>2</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>20</day>
<month>2</month>
<year>2020</year>
</pub-date>
<!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>. -->
<volume>4</volume>
<issue>2</issue>
<elocation-id>bvz039</elocation-id>
<history>
<date date-type="received">
<day>27</day>
<month>9</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>05</day>
<month>2</month>
<year>2020</year>
</date>
<date date-type="corrected-typeset">
<day>20</day>
<month>2</month>
<year>2020</year>
</date>
</history>
<permissions>
<copyright-statement>© Endocrine Society 2020.</copyright-statement>
<copyright-year>2020</copyright-year>
<license license-type="cc-by-nc-nd" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">
<license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com</license-p>
</license>
</permissions>
<self-uri xlink:href="bvz039.pdf"></self-uri>
<abstract>
<title>Abstract</title>
<p>The intestinal barrier is complex and consists of multiple layers, and it provides a physical and functional barrier to the transport of luminal contents to systemic circulation. While the epithelial cell layer and the outer/inner mucin layer constitute the physical barrier and are often referred to as the intestinal barrier, intestinal alkaline phosphatase (IAP) produced by epithelial cells and antibacterial proteins secreted by Panneth cells represent the functional barrier. While antibacterial proteins play an important role in the host defense against gut microbes, IAP detoxifies bacterial endotoxin lipopolysaccharide (LPS) by catalyzing the dephosphorylation of the active/toxic Lipid A moiety, preventing local inflammation as well as the translocation of active LPS into systemic circulation. The causal relationship between circulating LPS levels and the development of multiple diseases underscores the importance of detailed examination of changes in the “layers” of the intestinal barrier associated with disease development and how this dysfunction can be attenuated by targeted interventions. To develop targeted therapies for improving intestinal barrier function, it is imperative to have a deeper understanding of the intestinal barrier itself, the mechanisms underlying the development of diseases due to barrier dysfunction (eg, high circulating LPS levels), the assessment of intestinal barrier function under diseased conditions, and of how individual layers of the intestinal barrier can be beneficially modulated to potentially attenuate the development of associated diseases. This review summarizes the current knowledge of the composition of the intestinal barrier and its assessment and modulation for the development of potential therapies for barrier dysfunction-associated diseases.</p>
</abstract>
<kwd-group>
<kwd>layers of intestinal barrier</kwd>
<kwd>macrophage activation</kwd>
<kwd>chronic inflammation</kwd>
<kwd>metabolic diseases</kwd>
<kwd>diabetes</kwd>
<kwd>intestinal alkaline phosphatase</kwd>
</kwd-group>
<counts>
<page-count count="15"></page-count>
</counts>
</article-meta>
</front>
<body>
<p>In addition to being the main organ involved in the uptake of nutrients and water, the intestine also constitutes an essential barrier against harmful/toxic substances from the external environment entering the body mainly in the form of daily diet. Skin may be perceived as the main organ protecting against the exposure to environmental factors but compared to the total surface area of the skin, which is ~2 m<sup>2</sup>, the area of the important internal membranes exposed to environmental factors is ~100 m<sup>2</sup> and ~400 m<sup>2</sup> for the lungs and intestines, respectively. Furthermore, the number of microorganisms inhabiting the intestine or the gastrointestinal (GI) tract has been estimated to exceed 10<sup>14</sup>, which encompasses ∼10 times more bacterial cells than the number of human cells and over 100 times the amount of genomic content (microbiome) as the human genome [<xref ref-type="bibr" rid="CIT0001">1</xref>, <xref ref-type="bibr" rid="CIT0002">2</xref>]; a recently revised estimate suggests that the ratio of human:bacterial cells may be closer to 1:1 [<xref ref-type="bibr" rid="CIT0003">3</xref>]. Under normal conditions, gut microbiota offer many benefits to the host, such as harvesting energy [<xref ref-type="bibr" rid="CIT0004">4</xref>], protecting against pathogens [<xref ref-type="bibr" rid="CIT0005">5</xref>], and regulating host immunity [<xref ref-type="bibr" rid="CIT0006">6</xref>]. This beneficial relationship is likely to be disrupted as a result of an altered microbial composition, known as dysbiosis, and extensive research efforts are currently directed towards the evaluation of specific changes in bacterial composition during dysbiosis. However, for dysbiosis-dependent changes to influence host metabolism and/or pathology will require direct interaction with, and subsequent modulation of, the intestinal barrier, underscoring the importance of detailed understanding and characterization of the intestinal barrier, per se.</p>
<sec id="s1">
<title>1. What is Intestinal Barrier? The 4 Layers of the Intestinal Barrier</title>
<p>The GI tract is subjected daily to thousands of microorganisms and nutrient components via the ingested diet. Maintenance of gut homeostasis therefore requires a complex system capable of performing several functions, such as the detoxification of bacteria-derived endotoxins, limiting direct contact/interaction with bacteria or pathogens, regulating the absorption of nutrients while restricting the transport of toxic substances or bacteria, and mounting an immune response or limiting the growth of pathogenic bacteria. Accordingly, the gut or intestinal barrier has evolved as a functional unit organized in a multilayer system (<xref ref-type="fig" rid="F1">Fig. 1</xref>), providing a physical as well as a functional barrier. The multiple layers of this barrier, starting from intestinal lumen to systemic circulation, include: (1) luminal intestinal alkaline phosphatase (IAP) that dephosphorylates bacterial endotoxin lipopolysaccharide (LPS) to detoxify it; (2) the mucus layer that provides a physical barrier preventing interactions between gut bacteria and intestinal epithelial cells; (3) the tight junctions between the epithelial cells that limit the paracellular transport of bacteria and/or bacterial products to systemic circulation; and (4) the antibacterial proteins secreted by the specialized intestinal epithelial cells or the Paneth cells and IgA secreted by the immune cells present in lamina propria underlying the epithelial cell layer.</p>
<fig id="F1" orientation="portrait" position="float">
<label>Figure 1.</label>
<caption>
<p>The “layers” of the intestinal barrier. Functional intestinal barrier consists of four “layers” (shown by numbers 1–4) extending from the lumen that contains gut bacteria and bacterial endotoxin LPS. Layer 1, or intestinal alkaline phosphatase (IAP), released from the intestinal epithelial cells, dephosphorylates luminal LPS inactive, producing dephospho-LPS. Mucin layer (layer 2), consisting of a firmly attached inner layer and a loose outer layer provide the first physical barrier restricting the interaction between luminal bacteria and epithelial cells. A single layer of epithelial cells (layer 3) separates the lumen from systemic circulation. Specialized secretory cells of the epithelial layer, namely goblet and Paneth cells, contribute to the formation of the mucin layer and the production of antibacterial proteins, respectively. Panneth cell-derived antibacterial proteins/peptides, along with secreted IgA (sIgA) from plasma cells present in the lamina propria, restrict bacterial growth and represent the fourth layer (layer 4) of the intestinal barrier.</p>
</caption>
<graphic xlink:href="bvz039f0001"></graphic>
</fig>
<sec id="s2">
<title>A. Layer 1, or the Intestinal Alkaline Phosphatase</title>
<p>Intestinal alkaline phosphatase is expressed and secreted by intestinal epithelial cells and remains active within the mucosal layer as well as the intestinal lumen. In addition to regulating bicarbonate secretion and duodenal surface pH and long chain fatty acid absorption, IAP removes phosphate groups from substrates such as bacterial endotoxin LPS and pathogen-associated molecular patterns (eg, flagellin, CpG DNA), and it reduces local intestinal inflammation [<xref ref-type="bibr" rid="CIT0007">7</xref>]. In addition, it also dephosphorylates adenosine tri-phosphate (ATP) and adenosine diphosphate (ADP) in the lumen; high levels of luminal ATP inhibits the growth of commensal bacteria and disrupts bacterial homeostasis [<xref ref-type="bibr" rid="CIT0008">8</xref>]. While all these functions of IAP are important to maintaining intestinal homeostasis, it is the ability of IAP to inactivate LPS that places IAP as the luminal first line of defense [<xref ref-type="bibr" rid="CIT0007">7</xref>]. LPS, a constituent of the cell wall of gram-negative bacteria, is abundant in the GI tract and is responsible for causing systemic inflammation and septic shock. The toxicity of LPS resides in the Lipid-A moiety, which permits it to bind to toll-like receptor-4 (TLR4). Removal of 1 of the 2 phosphate groups on the Lipid-A moiety reduces LPS toxicity 100 fold [<xref ref-type="bibr" rid="CIT0009">9</xref>]. Dephospho-LPS still binds to TLR4 but predominantly acts as a TLR4 antagonist [<xref ref-type="bibr" rid="CIT0010">10</xref>]. This reduction in the toxicity of LPS inhibits downstream intracellular signaling [<xref ref-type="bibr" rid="CIT0011">11</xref>], leading to a reduction in NF-κB activation and the release of proinflammatory cytokines.</p>
</sec>
<sec id="s3">
<title>B. Layer 2, or the Mucus Layer</title>
<p>In contrast to IAP representing a “functional” barrier, the intestinal mucosal layer (or the second layer of the intestinal barrier) is the first “physical” barrier encountered by bacteria in the GI tract. It is composed of 2 layers: an inner layer that is firmly attached to the epithelial cells and an outer layer that is thicker but much looser and less adherent. The inner mucosal layer does not allow bacteria to penetrate, keeping the surface of epithelial cells free of direct contact with bacteria. In contrast, the outer mucosal layer harbors commensal bacteria that prevent the entry of pathogenic bacteria into the outer as well as inner mucus layer. Consistently, an increase in the number of mucus-residing commensal bacteria by pro- or prebiotic interventions is thought to improve the barrier function of the mucosal layer [<xref ref-type="bibr" rid="CIT0012">12</xref>]. These 2 mucosal layers consist of water (~95%) and glycoproteins (1–10%), as well as electrolytes, antibodies, and nucleic acids [<xref ref-type="bibr" rid="CIT0013">13</xref>]. Highly glycated protein mucin (MUC2) is the major glycoprotein secreted by specialized epithelial cells called goblet cells. After secretion, MUC2 organizes in a hydrated and expanded network with other secreted proteins, forming an organized mucous layer. The amount and composition of the mucus layer reflects a balance between mucus secretion and its erosion and degradation by bacteria [<xref ref-type="bibr" rid="CIT0014">14</xref>]. Depletion of the mucus layer either by increased degradation or deficient synthesis will, therefore, have a profound effect on this layer of the intestinal barrier. Consistently, Muc2-/- mice have increased bacterial adherence to the intestinal epithelium, enhanced susceptibility to colitis, and disrupted intestinal barrier function [<xref ref-type="bibr" rid="CIT0015">15</xref>].</p>
</sec>
<sec id="s4">
<title>C. Layer 3, or the Epithelium</title>
<p>The intestinal epithelium is a single layer of cells that acts as a highly selective barrier preventing the passage of harmful luminal contents such as foreign antigens, microorganisms, and their toxins while allowing the translocation of essential dietary nutrients, electrolytes, and water from the intestinal lumen into the systemic circulation. This selectivity of transport is mediated by the regulation of 2 major mechanisms, namely the transepithelial/transcellular and paracellular transport pathways. In addition, this epithelial layer is also considered nonpermissive for endocytic uptake by any mechanism, largely due to unusually high amounts of glycolipids that are organized in lipid raft microdomains [<xref ref-type="bibr" rid="CIT0016">16</xref>] stabilized by divalent galectin-4 [<xref ref-type="bibr" rid="CIT0017">17</xref>]. Nutrients such as amino acids [<xref ref-type="bibr" rid="CIT0018">18</xref>], electrolytes [<xref ref-type="bibr" rid="CIT0019">19</xref>], short chain fatty acids, and sugars [<xref ref-type="bibr" rid="CIT0020">20</xref>] are routinely transported via the transcellular pathway through the epithelial cells, and this uptake is predominantly regulated by selective transporters. Transport through the space between epithelial cells, or paracellular transport, is regulated by intercellular complexes localized at the apical-lateral membrane junction and along the lateral membrane [<xref ref-type="bibr" rid="CIT0021">21</xref>, <xref ref-type="bibr" rid="CIT0022">22</xref>]. These intercellular complexes include desmosomes, adherens junctions, and tight junctions [<xref ref-type="bibr" rid="CIT0023">23</xref>]. Adhesive junctional complexes and desmosomes are important in the mechanical linkage of adjacent cells and consist of transmembrane proteins that link adjacent cells to the actin cytoskeleton via cytoplasmic scaffolding proteins [<xref ref-type="bibr" rid="CIT0024">24</xref>]. The tight junctions, on the other hand, are responsible for sealing the intercellular space and thereby regulating paracellular transport [<xref ref-type="bibr" rid="CIT0025">25</xref>]. Tight junctions are formed by proteins such as occludins and members of the claudin family that cross the plasma membrane to interact with proteins from the adjoining cell. On the intracellular side of the membrane, the carboxyl terminal ends of these proteins interact with other tight junction proteins such as ZO-1, ZO-2, and ZO-3. Intracellularly, these proteins associate with a ring of actin microfilaments (for a detailed review of the organization of tight junction proteins, see [<xref ref-type="bibr" rid="CIT0021">21</xref>, <xref ref-type="bibr" rid="CIT0026">26</xref>]). Consequently, the integrity of the epithelial cell layer and tight junction proteins is often referred to as the “intestinal barrier” despite the important contributions of the other three “layers.”</p>
</sec>
<sec id="s5">
<title>D. Layer 4, or the Antibacterial Peptides</title>
<p>In addition to providing a single cell layer physical barrier, the specialized secretory cells of the intestinal epithelium or the Paneth cells [<xref ref-type="bibr" rid="CIT0027">27</xref>] located at the base of small intestinal crypts, act as important effectors of innate immunity though the secretion of antimicrobial peptides that play an important role in the host defense against gut microbes [<xref ref-type="bibr" rid="CIT0028">28</xref>]. Thus, secreted antibacterial peptides constitute the “fourth” layer of the intestinal barrier. The most abundant antimicrobial peptide in the human intestine is α-defensin, a member of the defensing family of peptides. Both α- and β-defensins are bacteriocidal, with activity against Gram-negative as well as Gram-positive bacteria. Numerous studies have suggested that the disruption of genes involved in the expression and secretion of these antimicrobial peptides increases the susceptibility to inflammatory bowel disease, for example, X-box binding protein (Xbp-1) [<xref ref-type="bibr" rid="CIT0029">29</xref>], autophagy-related 16-like 1 (Atg16l1) [<xref ref-type="bibr" rid="CIT0030">30</xref>], nucleotide binding oligomerization domain-containing 2 (Nod2) [<xref ref-type="bibr" rid="CIT0031">31</xref>], and transcription factor 4 (Tcf4) [<xref ref-type="bibr" rid="CIT0032">32</xref>]. Consistently, Crohn’s disease patients not only have a reduced number of healthy Paneth cells but also a decreased expression of β-defensins in the areas of acute inflammation [<xref ref-type="bibr" rid="CIT0033">33</xref>]. Recent studies have also implicated the important role of amino acids in regulating the expression of antimicrobial peptides [<xref ref-type="bibr" rid="CIT0034">34</xref>]. For example, aberrations in tryptophan metabolism causes intestinal inflammation via changes in the expression of antibacterial proteins [<xref ref-type="bibr" rid="CIT0035">35</xref>], and a glutamine-mediated increase in the expression of these proteins underlies the reduced gut inflammation observed in animal models [<xref ref-type="bibr" rid="CIT0036">36–38</xref>]. Collectively, these studies provide a direct link between disruptions of this layer of intestinal barrier function to disease development.</p>
<p>In addition to the antibacterial proteins secreted by Paneth cells, IgA secreted (sIgA) by plasma immune cells present in lamina propria also plays a significant role in limiting direct interactions between pathogens and the epithelial cell monolayer. The primary mechanism of sIgA-mediated protection is immune exclusion wherein direct sIgA binding to microorganisms or toxins prevents colonization or toxicity/damage to the epithelial cells [<xref ref-type="bibr" rid="CIT0039">39</xref>]. Within the lamina propria itself, IgA binds to the various immune complexes and facilitates their removal and attenuates systemic inflammatory responses [<xref ref-type="bibr" rid="CIT0040">40</xref>]. Humans secrete an estimated 3 g of sIgA into the intestinal lumen every day, reflecting its important role in protecting the mucosal surface. B-cell deficient mice or mice lacking the immunoglobulin receptor required for sIgA transport to the lumen display enhanced stimulation of innate responses in gut epithelial cells, further demonstrating the role of adaptive immune responses in regulating intestinal inflammation [<xref ref-type="bibr" rid="CIT0041">41</xref>].</p>
</sec>
</sec>
<sec id="s6">
<title>2. Consequences of Intestinal Barrier Dysfunction: Local and Systemic Inflammation</title>
<p>Intestinal barrier function is critical for normal homeostasis of the gut, and the breakdown or dysfunction of this barrier is associated with local as well as systemic consequences largely related to direct contact of bacteria/bacterial products with the epithelial cells, and translocation of these to the systemic circulation (<xref ref-type="fig" rid="F2">Fig. 2</xref>). Direct contact with bacteria/bacterial products leads to the activation of immune cells via TLR4/MyD88-dependent signaling pathways in the lamina propria by interaction with gut bacteria–derived LPS, resulting in the secretion of proinflammatory mediators that perpetuate local inflammation. Consistently, intraperitoneal administration of the LPS-TLR4 signaling inhibitor TAK-242 attenuates these consequences of intestinal barrier disruption [<xref ref-type="bibr" rid="CIT0042">42</xref>]. Local intestinal inflammation underlies the development of a number of gastrointestinal diseases, such as inflammatory bowel disease [<xref ref-type="bibr" rid="CIT0043">43</xref>], Crohn’s disease [<xref ref-type="bibr" rid="CIT0044">44</xref>], and ulcerative colitis (extensively reviewed recently in [<xref ref-type="bibr" rid="CIT0045">45</xref>]).</p>
<fig id="F2" orientation="portrait" position="float">
<label>Figure 2.</label>
<caption>
<p>Disruption of the intestinal barrier function. Under normal conditions with an intact barrier, while intestinal epithelial cells facilitate the transcellular movement of ions and nutrients, paracellular transport of bacteria/bacterial products such as LPS is restricted. Cells within the epithelial layer are sealed by tight junction proteins such as Occludin, Claudin, and ZO-1, preventing paracellular transport. In addition, appropriate/homeostatic expression of intestinal alkaline phosphatase (IAP) continuously dephosphorylates and detoxifies LPS in the luminal space. Lamina propria, below the epithelial layer, contains immune cells, both of the innate immune system (eg, macrophages, dendritic cells) and the adaptive immune system (eg, T-cells and IgA-producing plasma celsl [not shown here]). When the intestinal barrier is disrupted (eg, by a Western diet, pathogenic bacteria, LPS due to inadequate detoxification by reduced IAP levels, etc.), the tight junctions are disordered, allowing for paracellular transport of LPS as well as luminal bacteria. In response to these stimuli, dendritic cells and/or macrophages are activated to produce proinflammatory cytokines that not only enhance further infiltration of immune cells into the lamia propria but also activate macrophages in circulation. Paracellularly transported bacteria and LPS also enter systemic circulation, resulting in increased systemic inflammation.</p>
</caption>
<graphic xlink:href="bvz039f0002"></graphic>
</fig>
<p>However, the major consequence of a disruption in the intestinal barrier is the increased paracellular transport of LPS into systemic circulation. In blood, LPS is carried bound to either LPS binding protein (LBP) or lipoproteins and interacts with surface receptors (eg, TLR4) on immune cells initiating an inflammatory response (<xref ref-type="fig" rid="F3">Fig. 3</xref>). TLR4 by itself cannot bind LPS but requires CD14 as a cofactor, which facilitates the transfer of LPS to TLR4 and MD2 that modulates LPS recognition. LPS binding protein shuttles LPS to CD14. The association of these auxiliary molecules triggers the signal resulting in the homodimerization of TLR4 and the consequent intracellular signaling via MyD88 [<xref ref-type="bibr" rid="CIT0011">11</xref>, <xref ref-type="bibr" rid="CIT0046">46</xref>]. This cascade then leads to the activation of NF-κB that results in increased transcription of proinflammatory cytokines such as TNFα, IL-1β, and IL-6 [<xref ref-type="bibr" rid="CIT0047">47</xref>]. Infiltration of activated macrophages or direct activation of resident macrophages in peripheral tissues by circulating LPS results in tissue inflammation. Further infiltration of immune cells (including neutrophils and monocytes) in response to this proinflammatory milieu perpetuates this inflammation, perturbing tissue homeostasis. For example, in the liver, increased inflammation leads to increased insulin resistance and lipogenesis resulting in fatty liver disease. Increased adipose tissue or skeletal muscle inflammation/insulin resistance underlies the development of diabetes. Increased infiltration of activated macrophages into the artery wall initiates atherogenesis.</p>
<fig id="F3" orientation="portrait" position="float">
<label>Figure 3.</label>
<caption>
<p>Consequences of disrupted intestinal barrier. Increased LPS in systemic circulation is causally linked to the development of multiple diseases. LPS associates with circulating lipoproteins and also interacts with LPS binding protein (LBP). LPS acts as a trigger for macrophage activation via LBP-dependent binding to TLR4. In co-ordination with MD2 and CD14, this results in the homodimerization of TLR4 and the initiation of intracellular signaling. Activation and nuclear translocation of proinflammatory transcription factor NF-κB leads to the eventual production of proinflammatory cytokines (eg, TNFα, IL-1β, IL-6), resulting in increased tissue inflammation. In the liver, LPS reaching through portal blood also activates resident macrophages or Kupffer cells, and increased inflammation underlies increased hepatic insulin resistance and lipogenesis. Activated macrophages infiltrate adipose tissue and the resulting inflamed adipose tissue is also insulin resistant and underlies the development of diabetes. Increased inflammation also leads to insulin resistance in skeletal muscles. Increased infiltration of LPS-activated macrophages into the artery wall initiates foam cell formation, resulting in atherosclerotic plaque development.</p>
</caption>
<graphic xlink:href="bvz039f0003"></graphic>
</fig>
</sec>
<sec id="s7">
<title>3. Disease Associated with Intestinal Barrier Dysfunction and LPS Translocation</title>
<p>Fiddian-Green first described the role of enhanced translocation of bacterial toxins or bacteria during cardiac surgery, contributing to morbidity and mortality, and indicated that a reduction in this breach of the intestinal barrier would improve outcomes [<xref ref-type="bibr" rid="CIT0048">48</xref>]. Severe endotoxemia is also seen during resuscitation after cardiac arrest, and ischemic injury to the intestine is considered to be the underlying trigger. In recent years the role of exogenous or dietary triggers in initiating barrier dysfunction is increasingly being recognized [<xref ref-type="bibr" rid="CIT0049">49</xref>, <xref ref-type="bibr" rid="CIT0050">50</xref>]. High fat, high cholesterol–containing Western-type diets that are responsible for the obesity epidemic and metabolic syndromes have been shown to increase intestinal permeability, resulting in the release of LPS into systemic circulation, leading to metabolic endotoxemia [<xref ref-type="bibr" rid="CIT0051">51–53</xref>]. Consistently, a continuous infusion of low-dose LPS to mimic metabolic endotoxemia leads to the development of Type 2 Diabetes Mellitus (T2DM) and atherosclerosis, emphasizing the causal relationship between intestinal barrier dysfunction and the development of metabolic diseases [<xref ref-type="bibr" rid="CIT0054">54</xref>]. Based on the observed changes in the intestinal mucosa, including a decreased number of goblet cells, diminished mucus production, reduced levels of secretory IgA, and increased translocation of bacteria/bacterial products to pancreatic lymph nodes, Miranda et al suggests that a disruption of the intestinal barrier function precedes the onset of Type 1 Diabetes Mellitus (T1DM) [<xref ref-type="bibr" rid="CIT0055">55</xref>]. Even in humans, obese phenotype is associated with endotoxemia, establishing the critical role of gut-derived LPS in the development of metabolic diseases [<xref ref-type="bibr" rid="CIT0056">56</xref>, <xref ref-type="bibr" rid="CIT0057">57</xref>].</p>
<p>In addition to diet-induced metabolic diseases,the presence of LPS in systemic circulation is also identified as a causal or complicating factor in diverse diseases such as autism [<xref ref-type="bibr" rid="CIT0058">58</xref>], Alzheimer’s disease [<xref ref-type="bibr" rid="CIT0059">59</xref>], Parkinson’s disease [<xref ref-type="bibr" rid="CIT0060">60</xref>], arthritis [<xref ref-type="bibr" rid="CIT0061">61</xref>], obesity-induced osteoarthritis [<xref ref-type="bibr" rid="CIT0062">62</xref>], asthma [<xref ref-type="bibr" rid="CIT0063">63</xref>], and several autoimmune diseases [<xref ref-type="bibr" rid="CIT0064">64</xref>]. People with multiple sclerosis also have altered biomarkers of intestinal barrier integrity [<xref ref-type="bibr" rid="CIT0065">65</xref>]. A chronic inflammatory state [<xref ref-type="bibr" rid="CIT0066">66</xref>] as well as endotoxin tolerance leading to a compensatory hypoinflammatory state is thought to underlie the immune-escape of cancer cells, directly linking circulating LPS to the likely development of multiple cancers [<xref ref-type="bibr" rid="CIT0067">67</xref>]. High LPS levels in the portal vein are also linked to the development and progression of hepatocellular carcinoma [<xref ref-type="bibr" rid="CIT0068">68</xref>]. Pasini et al showed that the improvement in glycemic control in T2DM subjects with chronic exercise was due to attenuation of intestinal barrier dysfunction [<xref ref-type="bibr" rid="CIT0069">69</xref>]. Changes in gut permeability are also involved in the pathogenesis of T1DM [<xref ref-type="bibr" rid="CIT0070">70</xref>]. These diverse reports establish the causal relationship between gut-derived LPS and the development of diseases, and they underscore the importance of the maintenance of the intestinal barrier function as well as targeted modulation as a novel therapeutic strategy.</p>
</sec>
<sec id="s8">
<title>4. Potential Therapies for Modulation Intestinal Barrier Function</title>
<p>Although targeted restoration of the intestinal barrier dysfunction seems to be a logical step in the modulation of 1 or more intestinal or systemic diseases, currently no therapies exist for clinical use. However, increased understanding of the multiple “layers” that constitute the overall intestinal barrier is likely to provide novel approaches for targeted modulation. Strategies examined in preclinical or clinical studies are discussed below in the context of the layers of the barrier. It needs to be emphasized that direct manipulation of the gut microbiome as a strategy to subsequently modulate intestinal inflammation is actively pursued and extensively reviewed [<xref ref-type="bibr" rid="CIT0071">71</xref>, <xref ref-type="bibr" rid="CIT0072">72</xref>] and is not the focus of this review.</p>
<sec id="s9">
<title>A. Modulation of Layer 1, or IAP</title>
<p>Preclinical studies have established the role of exogenous IAP administration on the improvement of intestinal barrier function and the subsequent attenuation of endotoxemia-mediated diseases. Kallannan et al demonstrated that orally supplemented IAP inhibited the absorption of LPS and prevented, as well as reversed, diet-induced metabolic syndrome in mice [<xref ref-type="bibr" rid="CIT0073">73</xref>]. Oral supplementation of IAP was also effective in ameliorating alcohol-induced hepatic steatosis in mice [<xref ref-type="bibr" rid="CIT0074">74</xref>] and, based on the IAP-mediated reversal of barrier dysfunction, Hamarneh et al suggested that enteral IAP supplementation may represent a novel approach to maintain the integrity of the intestinal barrier in critically ill patients with decreased IAP in ileal fluid samples [<xref ref-type="bibr" rid="CIT0075">75</xref>]. We recently reported the development of intestine-specific IAP transgenic mice over-expressing human chimeric IAP and demonstrated attenuation of a high fat, high cholesterol–containing Western-type diet-induced intestinal barrier dysfunction as well as improved glucose intolerance [<xref ref-type="bibr" rid="CIT0076">76</xref>], further establishing the validity of an IAP-based approach for improving barrier function. With concerns related to the partial degradation or inactivation of orally administered IAP during transit through a low gastric pH environment, intraduodenal administration of bovine IAP in 21 severe ulcerative colitis patients showed short-term improvement in disease activity scores and reductions in plasma C-reactive protein and stool calprotectin. More importantly, IAP treatment was well tolerated and was nonimmunogenic [<xref ref-type="bibr" rid="CIT0077">77</xref>] in human subjects. Extensive research is underway to identify dietary components with the potential to increase endogenous IAP expression/activity (reviewed in [<xref ref-type="bibr" rid="CIT0078">78</xref>]). We identified an increase in IAP as one of the mechanisms by which oral supplementation with curcumin protects against a high fat, high cholesterol–containing Western-type diet-induced barrier dysfunction and the subsequent development of glucose intolerance and atherosclerosis [<xref ref-type="bibr" rid="CIT0051">51</xref>]. It is noteworthy that curcumin is not absorbed and yet attenuates several diseases, and its gut-specific action now provides a mechanistic insight [<xref ref-type="bibr" rid="CIT0079">79</xref>].</p>
</sec>
<sec id="s10">
<title>B. Modulation of Layer 2, or the Mucin Layer</title>
<p>In the absence of adequate dietary fiber, colonic bacteria turn to the alternate energy source, the mucin-2 (MUC-2) glycoprotein-rich mucus layer [<xref ref-type="bibr" rid="CIT0080">80</xref>], leading to the erosion of the mucin layer and the disruption of the intestinal barrier [<xref ref-type="bibr" rid="CIT0081">81</xref>]. Therefore, fiber supplementation of western-type diets is a logical intervention to prevent or reverse the disruption of the mucin layer of the intestinal barrier. Okazaki et al demonstrated an increase in mucin by dietary fiber in rats that were fed a diet containing 30% lard [<xref ref-type="bibr" rid="CIT0082">82</xref>]. Similarly, a diet supplemented with homogeneous <italic>Dendrobium huoshanense polysaccharide</italic> increased the expression of Muc-2 in mice [<xref ref-type="bibr" rid="CIT0083">83</xref>]. Increased mucin expression is also noted in experimental animals with other dietary fiber supplementations, such as pea fiber [<xref ref-type="bibr" rid="CIT0084">84</xref>], fermented rice bran [<xref ref-type="bibr" rid="CIT0085">85</xref>], and fructo-oligosaccharides [<xref ref-type="bibr" rid="CIT0086">86</xref>], and it is associated with an improved intestinal barrier and a decreased bacterial translocation, leading to improved disease (eg, glucose intolerance, colitis, or steatohepatitis) status. Studies from our laboratory have demonstrated that the supplementation of a high fat, high cholesterol–containing Western-type diet with galactooligosaccharide fiber increased Muc-2 expression and maintained the continuity of the mucin layer. Despite there being no changes in plasma cholesterol levels, improved barrier function and reduced plasma LPS levels led to improved glucose tolerance and decreased atherosclerosis [<xref ref-type="bibr" rid="CIT0087">87</xref>].</p>
</sec>
<sec id="s11">
<title>C. Modulation of Layer 3, or the Epithelial Cell Layer</title>
<p>Strengthening this layer by reducing paracellular transport will require targeted regulation of intercellular junctional proteins. Increased immune activation of the epithelial cells leads to the increased production of TNFα and IL-13, which increase paracellular transport by interfering with the expression and/or organization of proteins within the tight junctions [<xref ref-type="bibr" rid="CIT0088">88</xref>, <xref ref-type="bibr" rid="CIT0089">89</xref>]. Consistently, anti-TNFα antibodies reduce the severity of inflammatory bowel disease in patients with active Crohn’s disease by restoring barrier function in the setting of a dampened immune system [<xref ref-type="bibr" rid="CIT0090">90</xref>, <xref ref-type="bibr" rid="CIT0091">91</xref>]. TNFα-induced loss of barrier function is also due to an increase in phosphorylation of myosin light chain (MLC) by MLC kinase, MLCK as demonstrated by in vitro studies using CaCo-2 monolayers [<xref ref-type="bibr" rid="CIT0092">92</xref>]. Consistently, the pharmacological inhibition of MLCK improves barrier function and diarrhea in mice [<xref ref-type="bibr" rid="CIT0093">93</xref>]. IL-13 induces the disruption of barrier function via upregulation of claudin-2 expression in cultured epithelial cell monolayers [<xref ref-type="bibr" rid="CIT0094">94</xref>], and whether targeted inhibition of IL-13 or claudin-2 will be beneficial and without significant effects on gut function is yet to be examined [<xref ref-type="bibr" rid="CIT0095">95</xref>]. Several phytochemicals improve intestinal permeability by targeting signaling pathways involved in the inflammation-mediated disruption of tight junction protein organization. For example, in addition to increasing IAP, curcumin also attenuates LPS or the IL-1β-induced disruption of tight junctions [<xref ref-type="bibr" rid="CIT0096">96</xref>]. Berberine reduces systemic LPS levels and also antagonizes the effects of LPS-mediated signaling through the Wnt/beta-catenin pathway to affect intestinal permeability in a rat model of sepsis [<xref ref-type="bibr" rid="CIT0097">97</xref>]. The hypoglycemic effects of berberine in Type 2 diabetic rats are related to the improvement in gut-derived hormones as well as the attenuation of intestinal barrier dysfunction [<xref ref-type="bibr" rid="CIT0098">98</xref>]. The stress hormone, cortisol, decreases the expression of tight junction proteins by reducing the binding of the glucocorticoid receptor (GR) to the occludin promoter region and increases paracellular permeability. These effects are blocked by lubiprostone, both in rodents and in humans, indicating that lubriptostone prevents stress-induced visceral hyperalgesia by changes in intestinal barrier function [<xref ref-type="bibr" rid="CIT0099">99</xref>]. In addition, lubiprostone supplementation also reduces atherosclerosis progression in ApoE-/- mice [<xref ref-type="bibr" rid="CIT0100">100</xref>]. Recently, Xu et al demonstrated the amelioration of barrier dysfunction in vitro by a novel GR agonist, 16α-hydroxytrametenolic acid (from edible mushrooms), through a GR-mediated PI3K/Akt/NF-κB signaling pathway [<xref ref-type="bibr" rid="CIT0101">101</xref>]. Hyperglycemia increases intestinal permeability via GLUT2-dependent transcriptional reprogramming of the intestinal cells, leading to the reduced expression of tight junction proteins, and in humans the systemic influx of intestinal bacteria-derived products correlates with individualized glycemic control [<xref ref-type="bibr" rid="CIT0102">102</xref>]. Consistently, the glucose lowering drug metformin protects against intestinal barrier dysfunction by the inhibition of JNK activation via an AMPKα1-dependent signaling pathway as demonstrated by using in vitro cell culture systems as well as colitis mouse models [<xref ref-type="bibr" rid="CIT0103">103</xref>].</p>
<p>Extensive research has also established the role of nutritional factors in improving overall intestinal permeability. These nutrients include antioxidants (Quercetin [<xref ref-type="bibr" rid="CIT0104">104</xref>], Ginkgo biloba extract [<xref ref-type="bibr" rid="CIT0105">105</xref>], N-acetyl cysteine [<xref ref-type="bibr" rid="CIT0106">106</xref>]) as well as probiotics and prebiotics [<xref ref-type="bibr" rid="CIT0107">107</xref>, <xref ref-type="bibr" rid="CIT0108">108</xref>]. Increasing knowledge of the specific role(s) of the various layers of the intestinal barrier is likely to provide opportunities for targeted improvement as needed to improve the efficacy of specific treatments. The assessment of intestinal barrier function and markers of disruption of one or more layers will be critical for the future development of these targeted strategies.</p>
</sec>
</sec>
<sec id="s12">
<title>5. Assessment of Intestinal Barrier Dysfunction</title>
<p>Direct assessment of intestinal barrier function is challenging given the invasiveness of intestinal tissue sampling. However, a number of methods are available to indirectly assess intestinal barrier function, and it is noteworthy that all methods have their own advantages and disadvantages. While some methods directly assess the permeability function in vivo, others rely on the measurement of specific markers in blood/plasma or feces.</p>
<sec id="s13">
<title>A. In Vivo Intestinal Permeability Assays: Determination of Urinary Lactulose/Mannitol Ratios</title>
<p>After the collection of a baseline or pretest urine sample, a sugar solution containing a mixture of lactulose and mannitol is orally administered. The larger size molecule (lactulose) can only cross the intestinal barrier by paracellular passage when the intestinal barrier is compromised. The smaller molecule (mannitol) crosses the epithelial barrier transcellularly and acts as a control for gastric emptying and dilution, transit time, and epithelial absorptive area, as well as systemic distribution and renal function. The urinary excretion ratio (lactulose:mannitol) is then used as a standardized assessment of intestinal permeability [<xref ref-type="bibr" rid="CIT0109">109</xref>]. While the noninvasiveness of this method is certainly an advantage, the complicated and elaborate methods for the analyses of excreted products makes it difficult to adapt to the routine measurements needed for clinical evaluation.</p>
</sec>
<sec id="s14">
<title>B. Circulating Biomarkers</title>
<p>Zonulin, a prehaptoglobin, is one of the physiological modulators that alters intestinal permeability by modifying protein-protein interactions within the tight junctions. Disruption of the intestinal barrier is associated with an increase in circulating as well as fecal zonulin [<xref ref-type="bibr" rid="CIT0110">110</xref>]. Caviglia et al demonstrated the suitability of serum zonulin levels in the evaluation of intestinal permeability in patients with inflammatory bowel disease [<xref ref-type="bibr" rid="CIT0111">111</xref>]. Intestinal fatty acid binding protein (I-FABP) is a small 14 kDa cytosolic protein specific to mature enterocytes. Its appearance in circulation indicates a breakdown of the enterocyte membrane [<xref ref-type="bibr" rid="CIT0112">112</xref>]. Diamine oxidase (DAO) is an intracellular enzyme present in the intestinal villi and is considered as a marker for the integrity of the intestinal epithelium. Circulating levels of DAO increase with damage and loss of intestinal barrier function [<xref ref-type="bibr" rid="CIT0113">113</xref>]. Due to increased paracellular transport of LPS and other proinflammatory mediators, plasma levels of LPS, LBP, IL-6, and IL-8 are also considered as markers of increased barrier dysfunction [<xref ref-type="bibr" rid="CIT0114">114–116</xref>].</p>
</sec>
<sec id="s15">
<title>C. Fecal Biomarkers</title>
<p>As stated above, increased levels of zonulin in the feces indicate a disruption of the intestinal barrier. Secretory immunoglobulin A (sIgA) is the main antibody found in the mucus membranes that are exposed to the environment, such as the nose, lungs, and the intestinal lining. Increase in fecal sIgA indicates intestinal inflammation and serves as a marker of barrier dysfunction. Increased neutrophil/eosinophil infiltration into the intestine is associated with damage to the gut lining. Therefore, calprotectin (produced by neutrophils) and eosinophil-derived neurotoxin are yet additional fecal markers of barrier disruption [<xref ref-type="bibr" rid="CIT0117">117</xref>].</p>
<p>Although not on the list of routine clinical tests, plasma or fecal markers of intestinal barrier function and/or inflammation are increasingly being utilized and, with more evidence of the causal relationship between intestinal barrier function and the development of multiple diseases, the use of these noninvasive tests is expected to increase. Linking the appearance of these or other novel markers to individual layers of the barrier would be the next challenge in developing targeted therapies.</p>
</sec>
</sec>
<sec id="s16">
<title>6. Summary and Conclusions</title>
<p>The causal relationship between chronic inflammation and the development of multiple diseases is increasingly being established, and the likely trigger for this low level, yet sustained systemic inflammation, is bacterial endotoxin LPS. While dietary components or intestinal injury (eg, by ischemia/reperfusion) may initiate the release of LPS from intestinal lumen to systemic circulation, the physical as well as the functional integrity of the intestinal barrier is the critical determinant of this translocation. This review summarizes the composition of the intestinal barrier, consequences of a dysfunctional barrier, and elaborates on the role of translocated LPS in the development of diseases. In addition, current knowledge on the successful manipulation of individual “layers” of the intestinal barrier is summarized. Discussion of the currently available tests emphasize the future use of the status of barrier function as a diagnostic parameter facilitating demonstration of causal relationship with pathogenesis of disease. The development of novel and more specific tests are expected to facilitate the identification of individual “layers” affected in a given disease process or person, leading to targeted interventions. For example, exogenous IAP supplementation or curcumin-mediated increase in IAP activity would be the therapeutic option where loss of IAP is identified. Galactooligosaccharide fiber supplementation would be the preferred option where mucosal layer disruption is evident. Phytochemicals and other nutritional supplements (eg, vitamin D) with demonstrated effects on improvement of tight junction protein expression/function are likely to be most beneficial where these disruptions are noted. Therefore, while correcting intestinal barrier dysfunction for modulation of multiple diseases can be envisioned as a viable therapeutic option, continuing progress in identifying the precise defect by use of specific biomarkers would facilitate targeted interventions.</p>
</sec>
</body>
<back>
<ack id="a1">
<title>Acknowledgments</title>
<p>
<bold><italic>Financial Support:</italic></bold> Innovative Basic Science Award from the American Diabetes Association 1-16-IBS-105 to SG.</p>
</ack>
<sec id="s111">
<title>Additional Information</title>
<p>
<bold><italic>Disclosure Summary:</italic></bold> The authors have nothing to disclose. </p>
</sec>
<ref-list id="r1">
<title>References and Notes</title>
<ref id="CIT0001">
<label>1.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Bäckhed</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Ley</surname><given-names>RE</given-names></name>, <name name-style="western"><surname>Sonnenburg</surname><given-names>JL</given-names></name>, <name name-style="western"><surname>Peterson</surname><given-names>DA</given-names></name>, <name name-style="western"><surname>Gordon</surname><given-names>JI</given-names></name></person-group>
<article-title>Host-bacterial mutualism in the human intestine</article-title>. <source/>Science.<year>2005</year>;<volume>307</volume>(<issue>5717</issue>):<fpage>1915</fpage>–<lpage>1920</lpage>.<pub-id pub-id-type="pmid">15790844</pub-id></mixed-citation>
</ref>
<ref id="CIT0002">
<label>2.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Gill</surname><given-names>SR</given-names></name>, <name name-style="western"><surname>Pop</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Deboy</surname><given-names>RT</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Metagenomic analysis of the human distal gut microbiome</article-title>. <source/>Science.<year>2006</year>;<volume>312</volume>(<issue>5778</issue>):<fpage>1355</fpage>–<lpage>1359</lpage>.<pub-id pub-id-type="pmid">16741115</pub-id></mixed-citation>
</ref>
<ref id="CIT0003">
<label>3.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Sender</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Fuchs</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Milo</surname><given-names>R</given-names></name></person-group>
<article-title>Revised estimates for the number of human and bacteria cells in the body</article-title>. <source/>Plos Biol.<year>2016</year>;<volume>14</volume>(<issue>8</issue>):<fpage>e1002533</fpage>.<pub-id pub-id-type="pmid">27541692</pub-id></mixed-citation>
</ref>
<ref id="CIT0004">
<label>4.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>den Besten</surname><given-names>G</given-names></name>, <name name-style="western"><surname>van Eunen</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Groen</surname><given-names>AK</given-names></name>, <name name-style="western"><surname>Venema</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Reijngoud</surname><given-names>DJ</given-names></name>, <name name-style="western"><surname>Bakker</surname><given-names>BM</given-names></name></person-group>
<article-title>The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism</article-title>. <source/>J Lipid Res.<year>2013</year>;<volume>54</volume>(<issue>9</issue>):<fpage>2325</fpage>–<lpage>2340</lpage>.<pub-id pub-id-type="pmid">23821742</pub-id></mixed-citation>
</ref>
<ref id="CIT0005">
<label>5.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Bäumler</surname><given-names>AJ</given-names></name>, <name name-style="western"><surname>Sperandio</surname><given-names>V</given-names></name></person-group>
<article-title>Interactions between the microbiota and pathogenic bacteria in the gut</article-title>. <source/>Nature.<year>2016</year>;<volume>535</volume>(<issue>7610</issue>):<fpage>85</fpage>–<lpage>93</lpage>.<pub-id pub-id-type="pmid">27383983</pub-id></mixed-citation>
</ref>
<ref id="CIT0006">
<label>6.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Gensollen</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Iyer</surname><given-names>SS</given-names></name>, <name name-style="western"><surname>Kasper</surname><given-names>DL</given-names></name>, <name name-style="western"><surname>Blumberg</surname><given-names>RS</given-names></name></person-group>
<article-title>How colonization by microbiota in early life shapes the immune system</article-title>. <source/>Science.<year>2016</year>;<volume>352</volume>(<issue>6285</issue>):<fpage>539</fpage>–<lpage>544</lpage>.<pub-id pub-id-type="pmid">27126036</pub-id></mixed-citation>
</ref>
<ref id="CIT0007">
<label>7.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Lallès</surname><given-names>JP</given-names></name></person-group>
<article-title>Intestinal alkaline phosphatase: novel functions and protective effects</article-title>. <source/>Nutr Rev.<year>2014</year>;<volume>72</volume>(<issue>2</issue>):<fpage>82</fpage>–<lpage>94</lpage>.<pub-id pub-id-type="pmid">24506153</pub-id></mixed-citation>
</ref>
<ref id="CIT0008">
<label>8.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Malo</surname><given-names>MS</given-names></name>, <name name-style="western"><surname>Moaven</surname><given-names>O</given-names></name>, <name name-style="western"><surname>Muhammad</surname><given-names>N</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Intestinal alkaline phosphatase promotes gut bacterial growth by reducing the concentration of luminal nucleotide triphosphates</article-title>. <source/>Am J Physiol Gastrointest Liver Physiol.<year>2014</year>;<volume>306</volume>(<issue>10</issue>):<fpage>G826</fpage>–<lpage>G838</lpage>.<pub-id pub-id-type="pmid">24722905</pub-id></mixed-citation>
</ref>
<ref id="CIT0009">
<label>9.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Schromm</surname><given-names>AB</given-names></name>, <name name-style="western"><surname>Brandenburg</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Loppnow</surname><given-names>H</given-names></name>, <etal>et al.</etal></person-group>
<article-title>The charge of endotoxin molecules influences their conformation and IL-6-inducing capacity</article-title>. <source/>J Immunol.<year>1998</year>;<volume>161</volume>(<issue>10</issue>):<fpage>5464</fpage>–<lpage>5471</lpage>.<pub-id pub-id-type="pmid">9820522</pub-id></mixed-citation>
</ref>
<ref id="CIT0010">
<label>10.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Bentala</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Verweij</surname><given-names>WR</given-names></name>, <name name-style="western"><surname>Huizinga-Van der Vlag</surname><given-names>A</given-names></name>, <name name-style="western"><surname>van Loenen-Weemaes</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Meijer</surname><given-names>DK</given-names></name>, <name name-style="western"><surname>Poelstra</surname><given-names>K</given-names></name></person-group>
<article-title>Removal of phosphate from lipid A as a strategy to detoxify lipopolysaccharide</article-title>. <source/>Shock.<year>2002</year>;<volume>18</volume>(<issue>6</issue>):<fpage>561</fpage>–<lpage>566</lpage>.<pub-id pub-id-type="pmid">12462566</pub-id></mixed-citation>
</ref>
<ref id="CIT0011">
<label>11.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Lu</surname><given-names>YC</given-names></name>, <name name-style="western"><surname>Yeh</surname><given-names>WC</given-names></name>, <name name-style="western"><surname>Ohashi</surname><given-names>PS</given-names></name></person-group>
<article-title>LPS/TLR4 signal transduction pathway</article-title>. <source/>Cytokine.<year>2008</year>;<volume>42</volume>(<issue>2</issue>):<fpage>145</fpage>–<lpage>151</lpage>.<pub-id pub-id-type="pmid">18304834</pub-id></mixed-citation>
</ref>
<ref id="CIT0012">
<label>12.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Everard</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Belzer</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Geurts</surname><given-names>L</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Cross-talk between Akkermansia muciniphila and intestinal epithelium controls diet-induced obesity</article-title>. <source/>Proc Natl Acad Sci U S A.<year>2013</year>;<volume>110</volume>(<issue>22</issue>):<fpage>9066</fpage>–<lpage>9071</lpage>.<pub-id pub-id-type="pmid">23671105</pub-id></mixed-citation>
</ref>
<ref id="CIT0013">
<label>13.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Macfarlane</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Woodmansey</surname><given-names>EJ</given-names></name>, <name name-style="western"><surname>Macfarlane</surname><given-names>GT</given-names></name></person-group>
<article-title>Colonization of mucin by human intestinal bacteria and establishment of biofilm communities in a two-stage continuous culture system</article-title>. <source/>Appl Environ Microbiol.<year>2005</year>;<volume>71</volume>(<issue>11</issue>):<fpage>7483</fpage>–<lpage>7492</lpage>.<pub-id pub-id-type="pmid">16269790</pub-id></mixed-citation>
</ref>
<ref id="CIT0014">
<label>14.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Deplancke</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Gaskins</surname><given-names>HR</given-names></name></person-group>
<article-title>Microbial modulation of innate defense: goblet cells and the intestinal mucus layer</article-title>. <source/>Am J Clin Nutr.<year>2001</year>;<volume>73</volume>(<issue>6</issue>):<fpage>1131S</fpage>–<lpage>1141S</lpage>.<pub-id pub-id-type="pmid">11393191</pub-id></mixed-citation>
</ref>
<ref id="CIT0015">
<label>15.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Kissoon-Singh</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Moreau</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Trusevych</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Chadee</surname><given-names>K</given-names></name></person-group>
<article-title>Entamoeba histolytica exacerbates epithelial tight junction permeability and proinflammatory responses in Muc2(-/-) mice</article-title>. <source/>Am J Pathol.<year>2013</year>;<volume>182</volume>(<issue>3</issue>):<fpage>852</fpage>–<lpage>865</lpage>.<pub-id pub-id-type="pmid">23357502</pub-id></mixed-citation>
</ref>
<ref id="CIT0016">
<label>16.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Danielsen</surname><given-names>EM</given-names></name>, <name name-style="western"><surname>Hansen</surname><given-names>GH</given-names></name></person-group>
<article-title>Lipid raft organization and function in brush borders of epithelial cells</article-title>. <source/>Mol Membr Biol.<year>2006</year>;<volume>23</volume>(<issue>1</issue>):<fpage>71</fpage>–<lpage>79</lpage>.<pub-id pub-id-type="pmid">16611582</pub-id></mixed-citation>
</ref>
<ref id="CIT0017">
<label>17.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Hansen</surname><given-names>GH</given-names></name>, <name name-style="western"><surname>Immerdal</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Thorsen</surname><given-names>E</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Lipid rafts exist as stable cholesterol-independent microdomains in the brush border membrane of enterocytes</article-title>. <source/>J Biol Chem.<year>2001</year>;<volume>276</volume>(<issue>34</issue>):<fpage>32338</fpage>–<lpage>32344</lpage>.<pub-id pub-id-type="pmid">11389144</pub-id></mixed-citation>
</ref>
<ref id="CIT0018">
<label>18.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Bröer</surname><given-names>S</given-names></name></person-group>
<article-title>Amino acid transport across mammalian intestinal and renal epithelia</article-title>. <source/>Physiol Rev.<year>2008</year>;<volume>88</volume>(<issue>1</issue>):<fpage>249</fpage>–<lpage>286</lpage>.<pub-id pub-id-type="pmid">18195088</pub-id></mixed-citation>
</ref>
<ref id="CIT0019">
<label>19.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Kunzelmann</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Mall</surname><given-names>M</given-names></name></person-group>
<article-title>Electrolyte transport in the mammalian colon: mechanisms and implications for disease</article-title>. <source/>Physiol Rev.<year>2002</year>;<volume>82</volume>(<issue>1</issue>):<fpage>245</fpage>–<lpage>289</lpage>.<pub-id pub-id-type="pmid">11773614</pub-id></mixed-citation>
</ref>
<ref id="CIT0020">
<label>20.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Ferraris</surname><given-names>RP</given-names></name>, <name name-style="western"><surname>Diamond</surname><given-names>J</given-names></name></person-group>
<article-title>Regulation of intestinal sugar transport</article-title>. <source/>Physiol Rev.<year>1997</year>;<volume>77</volume>(<issue>1</issue>):<fpage>257</fpage>–<lpage>302</lpage>.<pub-id pub-id-type="pmid">9016304</pub-id></mixed-citation>
</ref>
<ref id="CIT0021">
<label>21.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Tsukita</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Furuse</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Itoh</surname><given-names>M</given-names></name></person-group>
<article-title>Multifunctional strands in tight junctions</article-title>. <source/>Nat Rev Mol Cell Biol.<year>2001</year>;<volume>2</volume>(<issue>4</issue>):<fpage>285</fpage>–<lpage>293</lpage>.<pub-id pub-id-type="pmid">11283726</pub-id></mixed-citation>
</ref>
<ref id="CIT0022">
<label>22.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Van Itallie</surname><given-names>CM</given-names></name>, <name name-style="western"><surname>Anderson</surname><given-names>JM</given-names></name></person-group>
<article-title>Claudins and epithelial paracellular transport</article-title>. <source/>Annu Rev Physiol.<year>2006</year>;<volume>68</volume>:<fpage>403</fpage>–<lpage>429</lpage>.<pub-id pub-id-type="pmid">16460278</pub-id></mixed-citation>
</ref>
<ref id="CIT0023">
<label>23.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Farquhar</surname><given-names>MG</given-names></name>, <name name-style="western"><surname>Palade</surname><given-names>GE</given-names></name></person-group>
<article-title>Junctional complexes in various epithelia</article-title>. <source/>J Cell Biol.<year>1963</year>;<volume>17</volume>:<fpage>375</fpage>–<lpage>412</lpage>.<pub-id pub-id-type="pmid">13944428</pub-id></mixed-citation>
</ref>
<ref id="CIT0024">
<label>24.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Hartsock</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Nelson</surname><given-names>WJ</given-names></name></person-group>
<article-title>Adherens and tight junctions: structure, function and connections to the actin cytoskeleton</article-title>. <source/>Biochim Biophys Acta.<year>2008</year>;<volume>1778</volume>(<issue>3</issue>):<fpage>660</fpage>–<lpage>669</lpage>.<pub-id pub-id-type="pmid">17854762</pub-id></mixed-citation>
</ref>
<ref id="CIT0025">
<label>25.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Schneeberger</surname><given-names>EE</given-names></name>, <name name-style="western"><surname>Lynch</surname><given-names>RD</given-names></name></person-group>
<article-title>Structure, function, and regulation of cellular tight junctions</article-title>. <source/>Am J Physiol.<year>1992</year>;<volume>262</volume>(<issue>6 Pt 1</issue>):<fpage>L647</fpage>–<lpage>L661</lpage>.<pub-id pub-id-type="pmid">1616050</pub-id></mixed-citation>
</ref>
<ref id="CIT0026">
<label>26.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Anderson</surname><given-names>JM</given-names></name></person-group>
<article-title>Molecular structure of tight junctions and their role in epithelial transport</article-title>. <source/>News Physiol Sci.<year>2001</year>;<volume>16</volume>:<fpage>126</fpage>–<lpage>130</lpage>.<pub-id pub-id-type="pmid">11443232</pub-id></mixed-citation>
</ref>
<ref id="CIT0027">
<label>27.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Porter</surname><given-names>EM</given-names></name>, <name name-style="western"><surname>Bevins</surname><given-names>CL</given-names></name>, <name name-style="western"><surname>Ghosh</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Ganz</surname><given-names>T</given-names></name></person-group>
<article-title>The multifaceted Paneth cell</article-title>. <source/>Cell Mol Life Sci.<year>2002</year>;<volume>59</volume>(<issue>1</issue>):<fpage>156</fpage>–<lpage>170</lpage>.<pub-id pub-id-type="pmid">11846026</pub-id></mixed-citation>
</ref>
<ref id="CIT0028">
<label>28.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Zasloff</surname><given-names>M</given-names></name></person-group>
<article-title>Antimicrobial peptides of multicellular organisms</article-title>. <source/>Nature.<year>2002</year>;<volume>415</volume>(<issue>6870</issue>):<fpage>389</fpage>–<lpage>395</lpage>.<pub-id pub-id-type="pmid">11807545</pub-id></mixed-citation>
</ref>
<ref id="CIT0029">
<label>29.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Kaser</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>AH</given-names></name>, <name name-style="western"><surname>Franke</surname><given-names>A</given-names></name>, <etal>et al.</etal></person-group>
<article-title>XBP1 links ER stress to intestinal inflammation and confers genetic risk for human inflammatory bowel disease</article-title>. <source/>Cell.<year>2008</year>;<volume>134</volume>(<issue>5</issue>):<fpage>743</fpage>–<lpage>756</lpage>.<pub-id pub-id-type="pmid">18775308</pub-id></mixed-citation>
</ref>
<ref id="CIT0030">
<label>30.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Cadwell</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>JY</given-names></name>, <name name-style="western"><surname>Brown</surname><given-names>SL</given-names></name>, <etal>et al.</etal></person-group>
<article-title>A key role for autophagy and the autophagy gene Atg16l1 in mouse and human intestinal Paneth cells</article-title>. <source/>Nature.<year>2008</year>;<volume>456</volume>(<issue>7219</issue>):<fpage>259</fpage>–<lpage>263</lpage>.<pub-id pub-id-type="pmid">18849966</pub-id></mixed-citation>
</ref>
<ref id="CIT0031">
<label>31.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Kobayashi</surname><given-names>KS</given-names></name>, <name name-style="western"><surname>Chamaillard</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Ogura</surname><given-names>Y</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract</article-title>. <source/>Science.<year>2005</year>;<volume>307</volume>(<issue>5710</issue>):<fpage>731</fpage>–<lpage>734</lpage>.<pub-id pub-id-type="pmid">15692051</pub-id></mixed-citation>
</ref>
<ref id="CIT0032">
<label>32.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Wehkamp</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Kübler</surname><given-names>I</given-names></name>, <etal>et al.</etal></person-group>
<article-title>The Paneth cell alpha-defensin deficiency of ileal Crohn’s disease is linked to Wnt/Tcf-4</article-title>. <source/>J Immunol.<year>2007</year>;<volume>179</volume>(<issue>5</issue>):<fpage>3109</fpage>–<lpage>3118</lpage>.<pub-id pub-id-type="pmid">17709525</pub-id></mixed-citation>
</ref>
<ref id="CIT0033">
<label>33.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Wehkamp</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Salzman</surname><given-names>NH</given-names></name>, <name name-style="western"><surname>Porter</surname><given-names>E</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Reduced Paneth cell alpha-defensins in ileal Crohn’s disease</article-title>. <source/>Proc Natl Acad Sci U S A.<year>2005</year>;<volume>102</volume>(<issue>50</issue>):<fpage>18129</fpage>–<lpage>18134</lpage>.<pub-id pub-id-type="pmid">16330776</pub-id></mixed-citation>
</ref>
<ref id="CIT0034">
<label>34.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Hashimoto</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Perlot</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Rehman</surname><given-names>A</given-names></name>, <etal>et al.</etal></person-group>
<article-title>ACE2 links amino acid malnutrition to microbial ecology and intestinal inflammation</article-title>. <source/>Nature.<year>2012</year>;<volume>487</volume>(<issue>7408</issue>):<fpage>477</fpage>–<lpage>481</lpage>.<pub-id pub-id-type="pmid">22837003</pub-id></mixed-citation>
</ref>
<ref id="CIT0035">
<label>35.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Nikolaus</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Schulte</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Al-Massad</surname><given-names>N</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Increased tryptophan metabolism is associated with activity of inflammatory bowel diseases</article-title>. <source/>Gastroenterol.<year>2017</year>;<volume>153</volume>(<issue>6</issue>):<fpage>1504</fpage>–<lpage>1516.e2</lpage>.</mixed-citation>
</ref>
<ref id="CIT0036">
<label>36.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Ren</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Duan</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Yin</surname><given-names>J</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Dietary L-glutamine supplementation modulates microbial community and activates innate immunity in the mouse intestine</article-title>. <source/>Amino Acids.<year>2014</year>;<volume>46</volume>(<issue>10</issue>):<fpage>2403</fpage>–<lpage>2413</lpage>.<pub-id pub-id-type="pmid">25023447</pub-id></mixed-citation>
</ref>
<ref id="CIT0037">
<label>37.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Vicario</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Amat</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Rivero</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Moretó</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Pelegrí</surname><given-names>C</given-names></name></person-group>
<article-title>Dietary glutamine affects mucosal functions in rats with mild DSS-induced colitis</article-title>. <source/>J Nutr.<year>2007</year>;<volume>137</volume>(<issue>8</issue>):<fpage>1931</fpage>–<lpage>1937</lpage>.<pub-id pub-id-type="pmid">17634266</pub-id></mixed-citation>
</ref>
<ref id="CIT0038">
<label>38.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Jeong</surname><given-names>SY</given-names></name>, <name name-style="western"><surname>Im</surname><given-names>YN</given-names></name>, <name name-style="western"><surname>Youm</surname><given-names>JY</given-names></name>, <etal>et al</etal></person-group>
<article-title>L-glutamine attenuates DSS-induced colitis via induction of MAPK phosphatase-1</article-title>. <source/>Nutrients.<year>2018</year>;<volume>10</volume>(<issue>3</issue>):<fpage>e288</fpage>.<pub-id pub-id-type="pmid">29494494</pub-id></mixed-citation>
</ref>
<ref id="CIT0039">
<label>39.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Mestecky</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Russell</surname><given-names>MW</given-names></name>, <name name-style="western"><surname>Elson</surname><given-names>CO</given-names></name></person-group>
<article-title>Intestinal IgA: novel views on its function in the defence of the largest mucosal surface</article-title>. <source/>Gut.<year>1999</year>;<volume>44</volume>(<issue>1</issue>):<fpage>2</fpage>–<lpage>5</lpage>.<pub-id pub-id-type="pmid">9862815</pub-id></mixed-citation>
</ref>
<ref id="CIT0040">
<label>40.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Kaetzel</surname><given-names>CS</given-names></name>, <name name-style="western"><surname>Robinson</surname><given-names>JK</given-names></name>, <name name-style="western"><surname>Chintalacharuvu</surname><given-names>KR</given-names></name>, <name name-style="western"><surname>Vaerman</surname><given-names>JP</given-names></name>, <name name-style="western"><surname>Lamm</surname><given-names>ME</given-names></name></person-group>
<article-title>The polymeric immunoglobulin receptor (secretory component) mediates transport of immune complexes across epithelial cells: a local defense function for IgA</article-title>. <source/>Proc Natl Acad Sci U S A.<year>1991</year>;<volume>88</volume>(<issue>19</issue>):<fpage>8796</fpage>–<lpage>8800</lpage>.<pub-id pub-id-type="pmid">1924341</pub-id></mixed-citation>
</ref>
<ref id="CIT0041">
<label>41.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Keilbaugh</surname><given-names>SA</given-names></name>, <name name-style="western"><surname>Shin</surname><given-names>ME</given-names></name>, <name name-style="western"><surname>Banchereau</surname><given-names>RF</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Activation of RegIIIbeta/gamma and interferon gamma expression in the intestinal tract of SCID mice: an innate response to bacterial colonisation of the gut</article-title>. <source/>Gut.<year>2005</year>;<volume>54</volume>(<issue>5</issue>):<fpage>623</fpage>–<lpage>629</lpage>.<pub-id pub-id-type="pmid">15831905</pub-id></mixed-citation>
</ref>
<ref id="CIT0042">
<label>42.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Horioka</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Tanaka</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Isozaki</surname><given-names>S</given-names></name>, <etal>et al</etal></person-group>
<article-title>Acute colchicine poisoning causes endotoxemia via the destruction of intestinal barrier function: the curative effect of endotoxin prevention in a murine model</article-title>. <source/>Dig Dis Sci.<year>2019</year>. doi: <pub-id pub-id-type="doi">10.1007/s10620-019-05729-w</pub-id>. [Epub ahead of print].</mixed-citation>
</ref>
<ref id="CIT0043">
<label>43.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Michielan</surname><given-names>A</given-names></name>, <name name-style="western"><surname>D’Incà</surname><given-names>R</given-names></name></person-group>
<article-title>Intestinal permeability in inflammatory bowel disease: pathogenesis, clinical evaluation, and therapy of leaky gut</article-title>. <source/>Mediators Inflamm.<year>2015</year>;<volume>2015</volume>:<fpage>628157</fpage>.<pub-id pub-id-type="pmid">26582965</pub-id></mixed-citation>
</ref>
<ref id="CIT0044">
<label>44.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Teshima</surname><given-names>CW</given-names></name>, <name name-style="western"><surname>Dieleman</surname><given-names>LA</given-names></name>, <name name-style="western"><surname>Meddings</surname><given-names>JB</given-names></name></person-group>
<article-title>Abnormal intestinal permeability in Crohn’s disease pathogenesis</article-title>. <source/>Ann N Y Acad Sci.<year>2012</year>;<volume>1258</volume>:<fpage>159</fpage>–<lpage>165</lpage>.<pub-id pub-id-type="pmid">22731729</pub-id></mixed-citation>
</ref>
<ref id="CIT0045">
<label>45.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Martini</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Krug</surname><given-names>SM</given-names></name>, <name name-style="western"><surname>Siegmund</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Neurath</surname><given-names>MF</given-names></name>, <name name-style="western"><surname>Becker</surname><given-names>C</given-names></name></person-group>
<article-title>Mend your fences: the epithelial barrier and its relationship with mucosal immunity in inflammatory bowel disease</article-title>. <source/>Cell Mol Gastroenterol Hepatol.<year>2017</year>;<volume>4</volume>(<issue>1</issue>):<fpage>33</fpage>–<lpage>46</lpage>.<pub-id pub-id-type="pmid">28560287</pub-id></mixed-citation>
</ref>
<ref id="CIT0046">
<label>46.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Pålsson-McDermott</surname><given-names>EM</given-names></name>, <name name-style="western"><surname>O’Neill</surname><given-names>LA</given-names></name></person-group>
<article-title>Signal transduction by the lipopolysaccharide receptor, Toll-like receptor-4</article-title>. <source/>Immunol.<year>2004</year>;<volume>113</volume>(<issue>2</issue>):<fpage>153</fpage>–<lpage>162</lpage>.</mixed-citation>
</ref>
<ref id="CIT0047">
<label>47.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Akira</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Takeda</surname><given-names>K</given-names></name></person-group>
<article-title>Toll-like receptor signalling</article-title>. <source/>Nat Rev Immunol.<year>2004</year>;<volume>4</volume>(<issue>7</issue>):<fpage>499</fpage>–<lpage>511</lpage>.<pub-id pub-id-type="pmid">15229469</pub-id></mixed-citation>
</ref>
<ref id="CIT0048">
<label>48.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Fiddian-Green</surname><given-names>RG</given-names></name></person-group>
<article-title>Gut mucosal ischemia during cardiac surgery</article-title>. <source/>Semin Thorac Cardiovasc Surg.<year>1990</year>;<volume>2</volume>(<issue>4</issue>):<fpage>389</fpage>–<lpage>399</lpage>.<pub-id pub-id-type="pmid">2091799</pub-id></mixed-citation>
</ref>
<ref id="CIT0049">
<label>49.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Mallick</surname><given-names>IH</given-names></name>, <name name-style="western"><surname>Yang</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Winslet</surname><given-names>MC</given-names></name>, <name name-style="western"><surname>Seifalian</surname><given-names>AM</given-names></name></person-group>
<article-title>Ischemia-reperfusion injury of the intestine and protective strategies against injury</article-title>. <source/>Dig Dis Sci.<year>2004</year>;<volume>49</volume>(<issue>9</issue>):<fpage>1359</fpage>–<lpage>1377</lpage>.<pub-id pub-id-type="pmid">15481305</pub-id></mixed-citation>
</ref>
<ref id="CIT0050">
<label>50.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Korth</surname><given-names>U</given-names></name>, <name name-style="western"><surname>Krieter</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Denz</surname><given-names>C</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Intestinal ischaemia during cardiac arrest and resuscitation: comparative analysis of extracellular metabolites by microdialysis</article-title>. <source/>Resuscitation.<year>2003</year>;<volume>58</volume>(<issue>2</issue>):<fpage>209</fpage>–<lpage>217</lpage>.<pub-id pub-id-type="pmid">12909384</pub-id></mixed-citation>
</ref>
<ref id="CIT0051">
<label>51.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Ghosh</surname><given-names>SS</given-names></name>, <name name-style="western"><surname>Bie</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Ghosh</surname><given-names>S</given-names></name></person-group>
<article-title>Oral supplementation with non-absorbable antibiotics or curcumin attenuates western diet-induced atherosclerosis and glucose intolerance in LDLR-/- mice–role of intestinal permeability and macrophage activation</article-title>. <source/>Plos One.<year>2014</year>;<volume>9</volume>(<issue>9</issue>):<fpage>e108577</fpage>.<pub-id pub-id-type="pmid">25251395</pub-id></mixed-citation>
</ref>
<ref id="CIT0052">
<label>52.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Moreira</surname><given-names>AP</given-names></name>, <name name-style="western"><surname>Texeira</surname><given-names>TF</given-names></name>, <name name-style="western"><surname>Ferreira</surname><given-names>AB</given-names></name>, <name name-style="western"><surname>Peluzio</surname><given-names>Mdo C</given-names></name>, <name name-style="western"><surname>Alfenas</surname><given-names>Rde C</given-names></name></person-group>
<article-title>Influence of a high-fat diet on gut microbiota, intestinal permeability and metabolic endotoxaemia</article-title>. <source/>Br J Nutr.<year>2012</year>;<volume>108</volume>(<issue>5</issue>):<fpage>801</fpage>–<lpage>809</lpage>.<pub-id pub-id-type="pmid">22717075</pub-id></mixed-citation>
</ref>
<ref id="CIT0053">
<label>53.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Pendyala</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Walker</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Holt</surname><given-names>PR</given-names></name></person-group>
<article-title>A high-fat diet is associated with endotoxemia that originates from the gut</article-title>. <source/>Gastroenterol.<year>2012</year>;<volume>142</volume>(<issue>5</issue>):<fpage>1100</fpage>–<lpage>1101.e2</lpage>.</mixed-citation>
</ref>
<ref id="CIT0054">
<label>54.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Cani</surname><given-names>PD</given-names></name>, <name name-style="western"><surname>Amar</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Iglesias</surname><given-names>MA</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Metabolic endotoxemia initiates obesity and insulin resistance</article-title>. <source/>Diabetes.<year>2007</year>;<volume>56</volume>(<issue>7</issue>):<fpage>1761</fpage>–<lpage>1772</lpage>.<pub-id pub-id-type="pmid">17456850</pub-id></mixed-citation>
</ref>
<ref id="CIT0055">
<label>55.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Miranda</surname><given-names>MCG</given-names></name>, <name name-style="western"><surname>Oliveira</surname><given-names>RP</given-names></name>, <name name-style="western"><surname>Torres</surname><given-names>L</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Frontline Science: abnormalities in the gut mucosa of non-obese diabetic mice precede the onset of type 1 diabetes</article-title>. <source/>J Leukoc Biol.<year>2019</year>;<volume>106</volume>(<issue>3</issue>):<fpage>513</fpage>–<lpage>529</lpage>.<pub-id pub-id-type="pmid">31313381</pub-id></mixed-citation>
</ref>
<ref id="CIT0056">
<label>56.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Creely</surname><given-names>SJ</given-names></name>, <name name-style="western"><surname>McTernan</surname><given-names>PG</given-names></name>, <name name-style="western"><surname>Kusminski</surname><given-names>CM</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes</article-title>. <source/>Am J Physiol Endocrinol Metab.<year>2007</year>;<volume>292</volume>(<issue>3</issue>):<fpage>E740</fpage>–<lpage>E747</lpage>.<pub-id pub-id-type="pmid">17090751</pub-id></mixed-citation>
</ref>
<ref id="CIT0057">
<label>57.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Kallio</surname><given-names>KA</given-names></name>, <name name-style="western"><surname>Hätönen</surname><given-names>KA</given-names></name>, <name name-style="western"><surname>Lehto</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Salomaa</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Männistö</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Pussinen</surname><given-names>PJ</given-names></name></person-group>
<article-title>Endotoxemia, nutrition, and cardiometabolic disorders</article-title>. <source/>Acta Diabetol.<year>2015</year>;<volume>52</volume>(<issue>2</issue>):<fpage>395</fpage>–<lpage>404</lpage>.<pub-id pub-id-type="pmid">25326898</pub-id></mixed-citation>
</ref>
<ref id="CIT0058">
<label>58.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Emanuele</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Orsi</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Boso</surname><given-names>M</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Low-grade endotoxemia in patients with severe autism</article-title>. <source/>Neurosci Lett.<year>2010</year>;<volume>471</volume>(<issue>3</issue>):<fpage>162</fpage>–<lpage>165</lpage>.<pub-id pub-id-type="pmid">20097267</pub-id></mixed-citation>
</ref>
<ref id="CIT0059">
<label>59.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Miller</surname><given-names>RG</given-names></name>, <name name-style="western"><surname>Gascon</surname><given-names>R</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Circulating endotoxin and systemic immune activation in sporadic amyotrophic lateral sclerosis (sALS)</article-title>. <source/>J Neuroimmunol.<year>2009</year>;<volume>206</volume>(<issue>1-2</issue>):<fpage>121</fpage>–<lpage>124</lpage>.<pub-id pub-id-type="pmid">19013651</pub-id></mixed-citation>
</ref>
<ref id="CIT0060">
<label>60.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Hasegawa</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Goto</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Tsuji</surname><given-names>H</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Intestinal dysbiosis and lowered serum lipopolysaccharide-binding protein in Parkinson’s disease</article-title>. <source/>Plos One.<year>2015</year>;<volume>10</volume>(<issue>11</issue>):<fpage>e0142164</fpage>.<pub-id pub-id-type="pmid">26539989</pub-id></mixed-citation>
</ref>
<ref id="CIT0061">
<label>61.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Fotis</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Shaikh</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Baszis</surname><given-names>KW</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Serologic evidence of gut-driven systemic inflammation in juvenile idiopathic arthritis</article-title>. <source/>J Rheumatol.<year>2017</year>;<volume>44</volume>(<issue>11</issue>):<fpage>1624</fpage>–<lpage>1631</lpage>.<pub-id pub-id-type="pmid">28916545</pub-id></mixed-citation>
</ref>
<ref id="CIT0062">
<label>62.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Metcalfe</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Harte</surname><given-names>AL</given-names></name>, <name name-style="western"><surname>Aletrari</surname><given-names>MO</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Does endotoxaemia contribute to osteoarthritis in obese patients?</article-title>
<source/>Clin Sci (Lond).
<year>2012</year>;<volume>123</volume>(<issue>11</issue>):<fpage>627</fpage>–<lpage>634</lpage>.<pub-id pub-id-type="pmid">22888972</pub-id></mixed-citation>
</ref>
<ref id="CIT0063">
<label>63.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Dubin</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Martin</surname><given-names>TR</given-names></name>, <name name-style="western"><surname>Swoveland</surname><given-names>P</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Asthma and endotoxin: lipopolysaccharide-binding protein and soluble CD14 in bronchoalveolar compartment</article-title>. <source/>Am J Physiol.<year>1996</year>;<volume>270</volume>(<issue>5 Pt 1</issue>):<fpage>L736</fpage>–<lpage>L744</lpage>.<pub-id pub-id-type="pmid">8967507</pub-id></mixed-citation>
</ref>
<ref id="CIT0064">
<label>64.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Fasano</surname><given-names>A</given-names></name></person-group>
<article-title>Leaky gut and autoimmune diseases</article-title>. <source/>Clin Rev Allergy Immunol.<year>2012</year>;<volume>42</volume>(<issue>1</issue>):<fpage>71</fpage>–<lpage>78</lpage>.<pub-id pub-id-type="pmid">22109896</pub-id></mixed-citation>
</ref>
<ref id="CIT0065">
<label>65.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Camara-Lemarroy</surname><given-names>CR</given-names></name>, <name name-style="western"><surname>Silva</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Greenfield</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>WQ</given-names></name>, <name name-style="western"><surname>Metz</surname><given-names>LM</given-names></name>, <name name-style="western"><surname>Yong</surname><given-names>VW</given-names></name></person-group>
<article-title>Biomarkers of intestinal barrier function in multiple sclerosis are associated with disease activity</article-title>. <source/>Mult Scler.<year>2019</year>. doi: <pub-id pub-id-type="doi">10.1177/1352458519863133</pub-id>. [Epub ahead of print]</mixed-citation>
</ref>
<ref id="CIT0066">
<label>66.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Djuric</surname><given-names>Z</given-names></name></person-group>
<article-title>Obesity-associated cancer risk: the role of intestinal microbiota in the etiology of the host proinflammatory state</article-title>. <source/>Transl Res.<year>2017</year>;<volume>179</volume>:<fpage>155</fpage>–<lpage>167</lpage>.<pub-id pub-id-type="pmid">27522986</pub-id></mixed-citation>
</ref>
<ref id="CIT0067">
<label>67.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Wirthgen</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Hoeflich</surname><given-names>A</given-names></name></person-group>
<article-title>Endotoxin-induced tryptophan degradation along the kynurenine pathway: the role of indolamine 2,3-dioxygenase and aryl hydrocarbon receptor-mediated immunosuppressive effects in endotoxin tolerance and cancer and its implications for immunoparalysis</article-title>. <source/>J Amino Acids.<year>2015</year>;<volume>2015</volume>:<fpage>973548</fpage>.<pub-id pub-id-type="pmid">26881062</pub-id></mixed-citation>
</ref>
<ref id="CIT0068">
<label>68.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Roderburg</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Luedde</surname><given-names>T</given-names></name></person-group>
<article-title>The role of the gut microbiome in the development and progression of liver cirrhosis and hepatocellular carcinoma</article-title>. <source/>Gut Microbes.<year>2014</year>;<volume>5</volume>(<issue>4</issue>):<fpage>441</fpage>–<lpage>445</lpage>.<pub-id pub-id-type="pmid">25006881</pub-id></mixed-citation>
</ref>
<ref id="CIT0069">
<label>69.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Pasini</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Corsetti</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Assanelli</surname><given-names>D</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Effects of chronic exercise on gut microbiota and intestinal barrier in human with type 2 diabetes</article-title>. <source/>Minerva Med.<year>2019</year>;<volume>110</volume>(<issue>1</issue>):<fpage>3</fpage>–<lpage>11</lpage>.<pub-id pub-id-type="pmid">30667205</pub-id></mixed-citation>
</ref>
<ref id="CIT0070">
<label>70.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Atkinson</surname><given-names>MA</given-names></name></person-group>
<article-title>The role for gut permeability in the pathogenesis of type 1 diabetes–a solid or leaky concept?</article-title><source/>Pediatr Diabetes.<year>2015</year>;<volume>16</volume>(<issue>7</issue>):<fpage>485</fpage>–<lpage>492</lpage>.<pub-id pub-id-type="pmid">26269193</pub-id></mixed-citation>
</ref>
<ref id="CIT0071">
<label>71.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Hills</surname><given-names>RD</given-names><suffix>Jr</suffix></name>, <name name-style="western"><surname>Pontefract</surname><given-names>BA</given-names></name>, <name name-style="western"><surname>Mishcon</surname><given-names>HR</given-names></name>, <name name-style="western"><surname>Black</surname><given-names>CA</given-names></name>, <name name-style="western"><surname>Sutton</surname><given-names>SC</given-names></name>, <name name-style="western"><surname>Theberge</surname><given-names>CR</given-names></name></person-group>
<article-title>Gut microbiome: profound implications for diet and disease</article-title>. <source/>Nutrients.<year>2019</year>; <volume>11</volume>(<issue>7</issue>):<fpage>E1613</fpage>.<pub-id pub-id-type="pmid">31315227</pub-id></mixed-citation>
</ref>
<ref id="CIT0072">
<label>72.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Peters</surname><given-names>VBM</given-names></name>, <name name-style="western"><surname>van de Steeg</surname><given-names>E</given-names></name>, <name name-style="western"><surname>van Bilsen</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Meijerink</surname><given-names>M</given-names></name></person-group>
<article-title>Mechanisms and immunomodulatory properties of pre- and probiotics</article-title>. <source/>Benef Microbes.<year>2019</year>;<volume>10</volume>(<issue>3</issue>):<fpage>225</fpage>–<lpage>236</lpage>.<pub-id pub-id-type="pmid">30827150</pub-id></mixed-citation>
</ref>
<ref id="CIT0073">
<label>73.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Kaliannan</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Hamarneh</surname><given-names>SR</given-names></name>, <name name-style="western"><surname>Economopoulos</surname><given-names>KP</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Intestinal alkaline phosphatase prevents metabolic syndrome in mice</article-title>. <source/>Proc Natl Acad Sci U S A.<year>2013</year>;<volume>110</volume>(<issue>17</issue>):<fpage>7003</fpage>–<lpage>7008</lpage>.<pub-id pub-id-type="pmid">23569246</pub-id></mixed-citation>
</ref>
<ref id="CIT0074">
<label>74.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Hamarneh</surname><given-names>SR</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>BM</given-names></name>, <name name-style="western"><surname>Kaliannan</surname><given-names>K</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Intestinal alkaline phosphatase attenuates alcohol-induced hepatosteatosis in mice</article-title>. <source/>Dig Dis Sci.<year>2017</year>;<volume>62</volume>(<issue>8</issue>):<fpage>2021</fpage>–<lpage>2034</lpage>.<pub-id pub-id-type="pmid">28424943</pub-id></mixed-citation>
</ref>
<ref id="CIT0075">
<label>75.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Hamarneh</surname><given-names>SR</given-names></name>, <name name-style="western"><surname>Mohamed</surname><given-names>MM</given-names></name>, <name name-style="western"><surname>Economopoulos</surname><given-names>KP</given-names></name>, <etal>et al.</etal></person-group>
<article-title>A novel approach to maintain gut mucosal integrity using an oral enzyme supplement</article-title>. <source/>Ann Surg.<year>2014</year>;<volume>260</volume>(<issue>4</issue>):<fpage>706</fpage>–<lpage>714</lpage>; discussion 714.<pub-id pub-id-type="pmid">25203888</pub-id></mixed-citation>
</ref>
<ref id="CIT0076">
<label>76.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Ghosh</surname><given-names>SS</given-names></name>, <name name-style="western"><surname>He</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Korzun</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Yannie</surname><given-names>PJ</given-names></name>, <name name-style="western"><surname>Ghosh</surname><given-names>S</given-names></name></person-group>
<article-title>Intestine-specific expression of human chimeric intestinal alkaline phosphatase attenuates Western diet-induced barrier dysfunction and glucose intolerance</article-title>. <source/>Physiol Rep.<year>2018</year>;<volume>6</volume>(<issue>14</issue>):<fpage>e13790</fpage>.<pub-id pub-id-type="pmid">30058275</pub-id></mixed-citation>
</ref>
<ref id="CIT0077">
<label>77.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Lukas</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Drastich</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Konecny</surname><given-names>M</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Exogenous alkaline phosphatase for the treatment of patients with moderate to severe ulcerative colitis</article-title>. <source/>Inflamm Bowel Dis.<year>2010</year>;<volume>16</volume>(<issue>7</issue>):<fpage>1180</fpage>–<lpage>1186</lpage>.<pub-id pub-id-type="pmid">19885903</pub-id></mixed-citation>
</ref>
<ref id="CIT0078">
<label>78.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Lalle`s</surname><given-names>JP</given-names></name></person-group>
<article-title>Recent advances in intestinal alkaline phosphatase, inflammation, and nutrition</article-title>. <source/>Nut Rev.<year>2019</year>;<volume>77</volume>(<issue>10</issue>):<fpage>710</fpage>–<lpage>724</lpage>.</mixed-citation>
</ref>
<ref id="CIT0079">
<label>79.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Ghosh</surname><given-names>SS</given-names></name>, <name name-style="western"><surname>He</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Gehr</surname><given-names>TW</given-names></name>, <name name-style="western"><surname>Ghosh</surname><given-names>S</given-names></name></person-group>
<article-title>Curcumin-mediated regulation of intestinal barrier function: the mechanism underlying its beneficial effects</article-title>. <source/>Tissue Barriers.<year>2018</year>;<volume>6</volume>(<issue>1</issue>):<fpage>e1425085</fpage>.<pub-id pub-id-type="pmid">29420166</pub-id></mixed-citation>
</ref>
<ref id="CIT0080">
<label>80.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Desai</surname><given-names>MS</given-names></name>, <name name-style="western"><surname>Seekatz</surname><given-names>AM</given-names></name>, <name name-style="western"><surname>Koropatkin</surname><given-names>NM</given-names></name>, <etal>et al.</etal></person-group>
<article-title>A dietary fiber-deprived gut microbiota degrades the colonic mucus barrier and enhances pathogen susceptibility</article-title>. <source/>Cell.<year>2016</year>;<volume>167</volume>(<issue>5</issue>):<fpage>1339</fpage>–<lpage>1353.e21</lpage>.<pub-id pub-id-type="pmid">27863247</pub-id></mixed-citation>
</ref>
<ref id="CIT0081">
<label>81.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Birchenough</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Schroeder</surname><given-names>BO</given-names></name>, <name name-style="western"><surname>Bäckhed</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Hansson</surname><given-names>GC</given-names></name></person-group>
<article-title>Dietary destabilisation of the balance between the microbiota and the colonic mucus barrier</article-title>. <source/>Gut Microbes.<year>2019</year>;<volume>10</volume>(<issue>2</issue>):<fpage>246</fpage>–<lpage>250</lpage>.<pub-id pub-id-type="pmid">30252606</pub-id></mixed-citation>
</ref>
<ref id="CIT0082">
<label>82.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Okazaki</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Katayama</surname><given-names>T</given-names></name></person-group>
<article-title>Consumption of non-digestible oligosaccharides elevates colonic alkaline phosphatase activity by up-regulating the expression of IAP-I, with increased mucins and microbial fermentation in rats fed a high-fat diet</article-title>. <source/>Br J Nutr.<year>2019</year>;<volume>121</volume>(<issue>2</issue>):<fpage>146</fpage>–<lpage>154</lpage>.<pub-id pub-id-type="pmid">30400998</pub-id></mixed-citation>
</ref>
<ref id="CIT0083">
<label>83.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Xie</surname><given-names>SZ</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Ye</surname><given-names>HY</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Dendrobium huoshanense polysaccharide regionally regulates intestinal mucosal barrier function and intestinal microbiota in mice</article-title>. <source/>Carbohydr Polym.<year>2019</year>;<volume>206</volume>:<fpage>149</fpage>–<lpage>162</lpage>.<pub-id pub-id-type="pmid">30553308</pub-id></mixed-citation>
</ref>
<ref id="CIT0084">
<label>84.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Hashemi</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Fouhse</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Im</surname><given-names>HS</given-names></name>, <name name-style="western"><surname>Chan</surname><given-names>CB</given-names></name>, <name name-style="western"><surname>Willing</surname><given-names>BP</given-names></name></person-group>
<article-title>Dietary pea fiber supplementation improves glycemia and induces changes in the composition of gut microbiota, serum short chain fatty acid profile and expression of mucins in glucose intolerant rats</article-title>. <source/>Nutrients.<year>2017</year>;<volume>9</volume>(<issue>11</issue>):<fpage>E1236</fpage>.<pub-id pub-id-type="pmid">29137145</pub-id></mixed-citation>
</ref>
<ref id="CIT0085">
<label>85.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Islam</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Koseki</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Watanabe</surname><given-names>K</given-names></name>, <etal>et al</etal></person-group>
<article-title>Dietary supplementation of fermented rice bran effectively alleviates dextran sodium sulfate-induced colitis in mice</article-title>. <source/>Nutrients.<year>2017</year>;<volume>9</volume>(<issue>7</issue>):<fpage>E747</fpage>.<pub-id pub-id-type="pmid">28703759</pub-id></mixed-citation>
</ref>
<ref id="CIT0086">
<label>86.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Matsumoto</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Ichimura</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Tsuneyama</surname><given-names>K</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Fructo-oligosaccharides and intestinal barrier function in a methionine-choline-deficient mouse model of nonalcoholic steatohepatitis</article-title>. <source/>Plos One.<year>2017</year>;<volume>12</volume>(<issue>6</issue>):<fpage>e0175406</fpage>.<pub-id pub-id-type="pmid">28632732</pub-id></mixed-citation>
</ref>
<ref id="CIT0087">
<label>87.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Ghosh</surname><given-names>SS</given-names></name>, <name name-style="western"><surname>Wnag</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Yannie</surname><given-names>PJ</given-names></name>, <name name-style="western"><surname>Sandhu</surname><given-names>YK</given-names></name>, <name name-style="western"><surname>Korzun</surname><given-names>WJ</given-names></name>, <name name-style="western"><surname>Ghosh</surname><given-names>S</given-names></name></person-group>
<article-title>Dietary supplementation with galactooligosaccharides attenuates high fat, high cholesterol diet-induced disruption of colonic mucin layer and improves glucose intolerance in C57BL/6 mice and reduces atherosclerosis in Ldlr-/- mice</article-title>. <source/>J Nutr.<year>2019</year> [In Press]</mixed-citation>
</ref>
<ref id="CIT0088">
<label>88.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Mankertz</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Amasheh</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Krug</surname><given-names>SM</given-names></name>, <etal>et al.</etal></person-group>
<article-title>TNFalpha up-regulates claudin-2 expression in epithelial HT-29/B6 cells via phosphatidylinositol-3-kinase signaling</article-title>. <source/>Cell Tissue Res.<year>2009</year>;<volume>336</volume>(<issue>1</issue>):<fpage>67</fpage>–<lpage>77</lpage>.<pub-id pub-id-type="pmid">19214581</pub-id></mixed-citation>
</ref>
<ref id="CIT0089">
<label>89.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Heller</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Florian</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Bojarski</surname><given-names>C</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution</article-title>. <source/>Gastroenterol.<year>2005</year>;<volume>129</volume>(<issue>2</issue>):<fpage>550</fpage>–<lpage>564</lpage>.</mixed-citation>
</ref>
<ref id="CIT0090">
<label>90.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Suenaert</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Bulteel</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Lemmens</surname><given-names>L</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Anti-tumor necrosis factor treatment restores the gut barrier in Crohn’s disease</article-title>. <source/>Am J Gastroenterol.<year>2002</year>;<volume>97</volume>(<issue>8</issue>):<fpage>2000</fpage>–<lpage>2004</lpage>.<pub-id pub-id-type="pmid">12190167</pub-id></mixed-citation>
</ref>
<ref id="CIT0091">
<label>91.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Baert</surname><given-names>FJ</given-names></name>, <name name-style="western"><surname>D’Haens</surname><given-names>GR</given-names></name>, <name name-style="western"><surname>Peeters</surname><given-names>M</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn’s ileocolitis</article-title>. <source/>Gastroenterol.<year>1999</year>;<volume>116</volume>(<issue>1</issue>):<fpage>22</fpage>–<lpage>28</lpage>.</mixed-citation>
</ref>
<ref id="CIT0092">
<label>92.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Graham</surname><given-names>WV</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Witkowski</surname><given-names>ED</given-names></name>, <name name-style="western"><surname>Schwarz</surname><given-names>BT</given-names></name>, <name name-style="western"><surname>Turner</surname><given-names>JR</given-names></name></person-group>
<article-title>Interferon-gamma and tumor necrosis factor-alpha synergize to induce intestinal epithelial barrier dysfunction by up-regulating myosin light chain kinase expression</article-title>. <source/>Am J Pathol.<year>2005</year>;<volume>166</volume>(<issue>2</issue>):<fpage>409</fpage>–<lpage>419</lpage>.<pub-id pub-id-type="pmid">15681825</pub-id></mixed-citation>
</ref>
<ref id="CIT0093">
<label>93.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Clayburgh</surname><given-names>DR</given-names></name>, <name name-style="western"><surname>Musch</surname><given-names>MW</given-names></name>, <name name-style="western"><surname>Leitges</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Fu</surname><given-names>YX</given-names></name>, <name name-style="western"><surname>Turner</surname><given-names>JR</given-names></name></person-group>
<article-title>Coordinated epithelial NHE3 inhibition and barrier dysfunction are required for TNF-mediated diarrhea in vivo</article-title>. <source/>J Clin Invest.<year>2006</year>;<volume>116</volume>(<issue>10</issue>):<fpage>2682</fpage>–<lpage>2694</lpage>.<pub-id pub-id-type="pmid">17016558</pub-id></mixed-citation>
</ref>
<ref id="CIT0094">
<label>94.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Weber</surname><given-names>CR</given-names></name>, <name name-style="western"><surname>Raleigh</surname><given-names>DR</given-names></name>, <name name-style="western"><surname>Su</surname><given-names>L</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Epithelial myosin light chain kinase activation induces mucosal interleukin-13 expression to alter tight junction ion selectivity</article-title>. <source/>J Biol Chem.<year>2010</year>;<volume>285</volume>(<issue>16</issue>):<fpage>12037</fpage>–<lpage>12046</lpage>.<pub-id pub-id-type="pmid">20177070</pub-id></mixed-citation>
</ref>
<ref id="CIT0095">
<label>95.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Odenwald</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Turner</surname><given-names>JR</given-names></name></person-group>
<article-title>The intestinal epithelial barrier: a therapeutic target?</article-title><source/>Nat Rev Gastroenterol Hepatol.<year>2017</year>;<volume>14</volume>(<issue>1</issue>):<fpage>9</fpage>–<lpage>21</lpage>.<pub-id pub-id-type="pmid">27848962</pub-id></mixed-citation>
</ref>
<ref id="CIT0096">
<label>96.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Ghosh</surname><given-names>SS</given-names></name>, <name name-style="western"><surname>Ghosh</surname><given-names>S</given-names></name></person-group>
<article-title>Curcumin improves intestinal barrier function: modulation of intracellular signaling, and organization of tight junctions</article-title>. <source/>Am J Physiol Cell Physiol.<year>2017</year>;<volume>312</volume>(<issue>4</issue>):<fpage>C438</fpage>–<lpage>C445</lpage>.<pub-id pub-id-type="pmid">28249988</pub-id></mixed-citation>
</ref>
<ref id="CIT0097">
<label>97.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>He</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Yuan</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Zuo</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Sun</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Feng</surname><given-names>A</given-names></name></person-group>
<article-title>Berberine exerts a protective effect on gut-vascular barrier via the modulation of the Wnt/beta-catenin signaling pathway during sepsis</article-title>. <source/>Cell Physiol Biochem.<year>2018</year>;<volume>49</volume>(<issue>4</issue>):<fpage>1342</fpage>–<lpage>1351</lpage>.<pub-id pub-id-type="pmid">30205381</pub-id></mixed-citation>
</ref>
<ref id="CIT0098">
<label>98.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Gong</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Hu</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Huang</surname><given-names>Z</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Berberine attenuates intestinal mucosal barrier dysfunction in type 2 diabetic rats</article-title>. <source/>Front Pharmacol.<year>2017</year>;<volume>8</volume>:<fpage>42</fpage>.<pub-id pub-id-type="pmid">28217099</pub-id></mixed-citation>
</ref>
<ref id="CIT0099">
<label>99.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Zong</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Zhu</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Zheng</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Wiley</surname><given-names>JW</given-names></name>, <name name-style="western"><surname>Hong</surname><given-names>S</given-names></name></person-group>
<article-title>Chronic stress and intestinal permeability: Lubiprostone regulates glucocorticoid receptor-mediated changes in colon epithelial tight junction proteins, barrier function, and visceral pain in the rodent and human</article-title>. <source/>Neurogastroenterol Motil.<year>2019</year>;<volume>31</volume>(<issue>2</issue>):<fpage>e13477</fpage>.<pub-id pub-id-type="pmid">30284340</pub-id></mixed-citation>
</ref>
<ref id="CIT0100">
<label>100.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Arakawa</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Ishigami</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Nakai-Sugiyama</surname><given-names>M</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Lubiprostone as a potential therapeutic agent to improve intestinal permeability and prevent the development of atherosclerosis in apolipoprotein E-deficient mice</article-title>. <source/>Plos One.<year>2019</year>;<volume>14</volume>(<issue>6</issue>):<fpage>e0218096</fpage>.<pub-id pub-id-type="pmid">31206525</pub-id></mixed-citation>
</ref>
<ref id="CIT0101">
<label>101.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Jurutka</surname><given-names>PW</given-names></name>, <etal>et al</etal></person-group>
<article-title>16α-Hydroxytrametenolic acid from Poria cocos improves intestinal barrier function through glucocorticoid receptor mediated PI3K/Akt/NF-κB pathway</article-title>. <source/>J Agric Food Chem.<year>2019</year>. doi: <pub-id pub-id-type="doi">10.1021/acs.jafc.9b04613</pub-id>. [Epub ahead of print]</mixed-citation>
</ref>
<ref id="CIT0102">
<label>102.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Thaiss</surname><given-names>CA</given-names></name>, <name name-style="western"><surname>Levy</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Grosheva</surname><given-names>I</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Hyperglycemia drives intestinal barrier dysfunction and risk for enteric infection</article-title>. <source/>Science.<year>2018</year>;<volume>359</volume>(<issue>6382</issue>):<fpage>1376</fpage>–<lpage>1383</lpage>.<pub-id pub-id-type="pmid">29519916</pub-id></mixed-citation>
</ref>
<ref id="CIT0103">
<label>103.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Deng</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Zeng</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Lai</surname><given-names>X</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Metformin protects against intestinal barrier dysfunction via AMPKα1-dependent inhibition of JNK signalling activation</article-title>. <source/>J Cell Mol Med.<year>2018</year>;<volume>22</volume>(<issue>1</issue>):<fpage>546</fpage>–<lpage>557</lpage>.<pub-id pub-id-type="pmid">29148173</pub-id></mixed-citation>
</ref>
<ref id="CIT0104">
<label>104.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Suzuki</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Hara</surname><given-names>H</given-names></name></person-group>
<article-title>Quercetin enhances intestinal barrier function through the assembly of zonula [corrected] occludens-2, occludin, and claudin-1 and the expression of claudin-4 in Caco-2 cells</article-title>. <source/>J Nutr.<year>2009</year>;<volume>139</volume>(<issue>5</issue>):<fpage>965</fpage>–<lpage>974</lpage>.<pub-id pub-id-type="pmid">19297429</pub-id></mixed-citation>
</ref>
<ref id="CIT0105">
<label>105.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Mustafa</surname><given-names>A</given-names></name>, <name name-style="western"><surname>El-Medany</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Hagar</surname><given-names>HH</given-names></name>, <name name-style="western"><surname>El-Medany</surname><given-names>G</given-names></name></person-group>
<article-title>Ginkgo biloba attenuates mucosal damage in a rat model of ulcerative colitis</article-title>. <source/>Pharmacol Res.<year>2006</year>;<volume>53</volume>(<issue>4</issue>):<fpage>324</fpage>–<lpage>330</lpage>.<pub-id pub-id-type="pmid">16458529</pub-id></mixed-citation>
</ref>
<ref id="CIT0106">
<label>106.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Lasson</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Olanders</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Deng</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Andersson</surname><given-names>R</given-names></name></person-group>
<article-title>Gut barrier permeability, reticuloendothelial system function and protease inhibitor levels following intestinal ischaemia and reperfusion–effects of pretreatment with N-acetyl-L-cysteine and indomethacin</article-title>. <source/>Dig Liver Dis.<year>2002</year>;<volume>34</volume>(<issue>8</issue>):<fpage>560</fpage>–<lpage>569</lpage>.<pub-id pub-id-type="pmid">12502212</pub-id></mixed-citation>
</ref>
<ref id="CIT0107">
<label>107.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>CC</given-names></name>, <name name-style="western"><surname>Walker</surname><given-names>WA</given-names></name></person-group>
<article-title>Probiotics and prebiotics: role in clinical disease states</article-title>. <source/>Adv Pediatr.<year>2005</year>;<volume>52</volume>:<fpage>77</fpage>–<lpage>113</lpage>.<pub-id pub-id-type="pmid">16124337</pub-id></mixed-citation>
</ref>
<ref id="CIT0108">
<label>108.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Fujimori</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Gudis</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Mitsui</surname><given-names>K</given-names></name>, <etal>et al.</etal></person-group>
<article-title>A randomized controlled trial on the efficacy of synbiotic versus probiotic or prebiotic treatment to improve the quality of life in patients with ulcerative colitis</article-title>. <source/>Nutrition.<year>2009</year>;<volume>25</volume>(<issue>5</issue>):<fpage>520</fpage>–<lpage>525</lpage>.<pub-id pub-id-type="pmid">19201576</pub-id></mixed-citation>
</ref>
<ref id="CIT0109">
<label>109.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>van Wijck</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Verlinden</surname><given-names>TJ</given-names></name>, <name name-style="western"><surname>van Eijk</surname><given-names>HM</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Novel multi-sugar assay for site-specific gastrointestinal permeability analysis: a randomized controlled crossover trial</article-title>. <source/>Clin Nutr.<year>2013</year>;<volume>32</volume>(<issue>2</issue>):<fpage>245</fpage>–<lpage>251</lpage>.<pub-id pub-id-type="pmid">22892368</pub-id></mixed-citation>
</ref>
<ref id="CIT0110">
<label>110.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Vanuytsel</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Vermeire</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Cleynen</surname><given-names>I</given-names></name></person-group>
<article-title>The role of Haptoglobin and its related protein, Zonulin, in inflammatory bowel disease</article-title>. <source/>Tissue Barriers.<year>2013</year>;<volume>1</volume>(<issue>5</issue>):<fpage>e27321</fpage>.<pub-id pub-id-type="pmid">24868498</pub-id></mixed-citation>
</ref>
<ref id="CIT0111">
<label>111.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Caviglia</surname><given-names>GP</given-names></name>, <name name-style="western"><surname>Dughera</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Ribaldone</surname><given-names>DG</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Serum zonulin in patients with inflammatory bowel disease: a pilot study</article-title>. <source/>Minerva Med.<year>2019</year>;<volume>110</volume>(<issue>2</issue>):<fpage>95</fpage>–<lpage>100</lpage>.<pub-id pub-id-type="pmid">30160088</pub-id></mixed-citation>
</ref>
<ref id="CIT0112">
<label>112.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Pelsers</surname><given-names>MM</given-names></name>, <name name-style="western"><surname>Hermens</surname><given-names>WT</given-names></name>, <name name-style="western"><surname>Glatz</surname><given-names>JF</given-names></name></person-group>
<article-title>Fatty acid-binding proteins as plasma markers of tissue injury</article-title>. <source/>Clin Chim Acta.<year>2005</year>;<volume>352</volume>(<issue>1-2</issue>):<fpage>15</fpage>–<lpage>35</lpage>.<pub-id pub-id-type="pmid">15653098</pub-id></mixed-citation>
</ref>
<ref id="CIT0113">
<label>113.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Honzawa</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Nakase</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Matsuura</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Chiba</surname><given-names>T</given-names></name></person-group>
<article-title>Clinical significance of serum diamine oxidase activity in inflammatory bowel disease: importance of evaluation of small intestinal permeability</article-title>. <source/>Inflamm Bowel Dis.<year>2011</year>;<volume>17</volume>(<issue>2</issue>):<fpage>E23</fpage>–<lpage>E25</lpage>.<pub-id pub-id-type="pmid">21225906</pub-id></mixed-citation>
</ref>
<ref id="CIT0114">
<label>114.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Pastor Rojo</surname><given-names>O</given-names></name>, <name name-style="western"><surname>López San Román</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Albéniz Arbizu</surname><given-names>E</given-names></name>, <name name-style="western"><surname>de la Hera Martínez</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Ripoll Sevillano</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Albillos Martínez</surname><given-names>A</given-names></name></person-group>
<article-title>Serum lipopolysaccharide-binding protein in endotoxemic patients with inflammatory bowel disease</article-title>. <source/>Inflamm Bowel Dis.<year>2007</year>;<volume>13</volume>(<issue>3</issue>):<fpage>269</fpage>–<lpage>277</lpage>.<pub-id pub-id-type="pmid">17206721</pub-id></mixed-citation>
</ref>
<ref id="CIT0115">
<label>115.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Liebregts</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Adam</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Bredack</surname><given-names>C</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Immune activation in patients with irritable bowel syndrome</article-title>. <source/>Gastroenterol.<year>2007</year>;<volume>132</volume>(<issue>3</issue>):<fpage>913</fpage>–<lpage>920</lpage>.</mixed-citation>
</ref>
<ref id="CIT0116">
<label>116.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Fujimoto</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Uemura</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Nakatani</surname><given-names>Y</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Plasma endotoxin and serum cytokine levels in patients with alcoholic hepatitis: relation to severity of liver disturbance</article-title>. <source/>Alcohol Clin Exp Res.<year>2000</year>;<volume>24</volume>(<issue>4 Suppl</issue>):<fpage>48S</fpage>–<lpage>54S</lpage>.<pub-id pub-id-type="pmid">10803780</pub-id></mixed-citation>
</ref>
<ref id="CIT0117">
<label>117.</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name name-style="western"><surname>Guardiola</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Lobatón</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Rodríguez-Alonso</surname><given-names>L</given-names></name>, <etal>et al.</etal></person-group>
<article-title>Fecal level of calprotectin identifies histologic inflammation in patients with ulcerative colitis in clinical and endoscopic remission</article-title>. <source/>Clin Gastroenterol Hepatol.<year>2014</year>;<volume>12</volume>(<issue>11</issue>):<fpage>1865</fpage>–<lpage>1870</lpage>.<pub-id pub-id-type="pmid">24993368</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>